Methods of treating cystic fibrosis

By using the CFTR modulator Compound I and its composition in combination with other CFTR modulators, the problem of poor enhancement of CFTR activity in existing treatment methods has been solved, significantly improved the physiological function of patients with cystic fibrosis and reduced the disease symptoms .

CN119095597APending Publication Date: 2024-12-06VERTEX PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380032388.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-03
Filing Date
2023-02-02
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing cystic fibrosis treatment methods have not yet fully cured the disease. The monotherapy of CFTR correction agents is not effective enough, and it is often used in combination with synergists to enhance CFTR activity. There is a lack of novel treatments for a variety of CFTR-mediated diseases. plan.

Method used

Provided is a CFTR modulator (Compound I) and a pharmaceutical composition thereof, including Compound I, deuterated derivatives thereof, and pharmaceutically acceptable salts for co-administration with other CFTR modulators for the treatment of cystic fibrosis and CFTR-mediated disease.

Benefits of technology

By enhancing the channel gating activity and cell surface stability of CFTR, the physiological function of patients is improved, the disease symptoms are alleviated, and the treatment effect is improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005069827050000021
    Figure BDA0005069827050000021
  • Figure BDA0005069827050000051
    Figure BDA0005069827050000051
  • Figure BDA0005069827050000052
    Figure BDA0005069827050000052
Patent Text Reader

Abstract

The present disclosure provides methods of treating cystic fibrosis or CFTR mediated diseases comprising administering Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing. The disclosure also provides pharmaceutical compositions comprising Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, and optionally comprising one or more additional CFTR modulators.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 306,344, filed on February 3, 2022, the contents of which are incorporated by reference in their entirety.

[0002] The present invention relates to modulators of the cystic fibrosis transmembrane conductance regulator (CFTR), pharmaceutical compositions containing the modulators, methods of using such modulators and pharmaceutical compositions to treat cystic fibrosis and CFTR-mediated disorders, and methods for preparing such modulators.

[0003] Cystic fibrosis (CF) is a recessive genetic disease that affects approximately 88,000 children and adults worldwide. Despite advances in treatment, CF remains incurable.

[0004] In CF patients, mutations in the endogenously expressed CFTR in the respiratory epithelium lead to reduced apical anion secretion, resulting in an imbalance in ion and fluid transport. The resulting reduction in anion transport leads to increased mucus accumulation in the lungs, and accompanied by microbial infections, ultimately leading to death in CF patients. In addition to respiratory diseases, CF patients often suffer from gastrointestinal problems and pancreatic insufficiency, which can lead to death if not treated. In addition, most men with cystic fibrosis are infertile, and women with cystic fibrosis have reduced fertility.

[0005] Sequence analysis of the CFTR gene has revealed a variety of disease-causing mutations (Cutting, GR et al. (1990) Nature 346:366-369; Dean, M et al. (1990) Cell 61:863:870; and Kerem, BS et al. (1989) Science 245:1073-1080; Kerem, BS et al. (1990) Proc. Natl. Acad. Sci. USA 87:8447-8451). To date, more than 2000 mutations in the CF gene have been identified; currently, the CFTR2 database contains information on at least 322 of these identified mutations, with sufficient evidence to define at least 281 mutations as pathogenic. The most common pathogenic mutation is a deletion of phenylalanine at position 508 of the CFTR amino acid sequence and is often referred to as the F508del mutation. This mutation is present in many cases of cystic fibrosis and is associated with severe disease.

[0006] CFTR is a cAMP / ATP-mediated anion channel expressed in various cell types including absorptive and secretory epithelial cells, wherein the CFTR regulates transmembrane anion flux and the activity of other ion channels and proteins. In epithelial cells, the normal function of CFTR is essential for maintaining the transport of electrolytes throughout the body (including respiratory and digestive tissues). CFTR is composed of 1480 amino acids encoding proteins, and the protein is composed of tandem repeats of transmembrane domains, each of which contains six transmembrane helices and nucleotide binding domains. Two transmembrane domains are connected with multiple phosphorylation sites by large polarity regulation (R) domains, thereby regulating channel activity and cellular transport.

[0007] Chloride transport is carried out by ENaC (epithelial sodium channel) and CFTR present on the apical membrane and by Na+ expressed on the basolateral surface of the cell. + -K + -ATPase pump and Cl - The secondary active transport of chloride from the luminal side leads to the accumulation of intracellular chloride, which can then be transported via Cl - Channels passively exit the cell, resulting in mediator transport. + / 2Cl - / K + Co-transporter, Na + -K + -ATPase pump and basolateral membrane K on the basolateral surface + The arrangement of channels and CFTR on the luminal side coordinates the secretion of chloride. Since water itself may not be actively transported, its flow across the epithelium depends on the small transepithelial osmotic gradient created by the bulk flow of sodium and chloride.

[0008] A variety of CFTR regulators have been identified recently. These regulators can be characterized as, for example, potentiators, correctors, potentiator enhancers / co-potentiators, amplifiers, read-through agents, and nucleic acid therapies. CFTR regulators that increase the channel gating activity of mutant and wild-type CFTR at the surface of epithelial cells are called potentiators. Correctors improve erroneous protein processing and the resulting transport to the epithelial surface. Ghelani and Schneider-Futschik (2020) ACS Pharmacology and Translational Science (ACS Pharmacol. Transl. Sci.) 3:4-10. The U.S. FDA has approved three CFTR correctors for the treatment of cystic fibrosis. However, monotherapy with some CFTR correctors has not been found to be effective enough, and therefore combination therapy with potentiators is often required to enhance CFTR activity. Currently, only one CFTR potentiator is approved for the treatment of cystic fibrosis. Therefore, novel treatments for cystic fibrosis and other CFTR-mediated diseases are needed.

[0009] Thus, one aspect of the present disclosure provides a CFTR modulating compound (6R, 12R)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol (Compound I), its deuterated derivatives, and pharmaceutically acceptable salts of any of the foregoing. Compound I can be depicted as having the following structure:

[0010]

[0011] Other aspects of the present disclosure provide pharmaceutical compositions comprising Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, which may further comprise at least one additional active pharmaceutical ingredient and / or at least one pharmaceutically acceptable carrier. Yet another aspect of the present disclosure is a method for treating CFTR-mediated disease cystic fibrosis, the method comprising administering Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing to a subject in need thereof, optionally as part of a pharmaceutical composition comprising at least one additional component.

[0012] Another aspect of the present invention provides a method for treating CFTR-mediated disease cystic fibrosis, the method comprising administering to a patient in need thereof Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, alone or in combination with one or more additional CFTR modulators selected from the group consisting of: (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylprop-2-yl ... )-1H-indol-5-yl)cyclopropanecarboxamide (Compound II), N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (also known as N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide) (Compound III) or N-(2-(tert-butyl)-5-hydroxy-4-(2-(methyl-d3)propan-2-yl)-1,1,1, 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound IV), N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)pyrazol-1-yl]-2-[(4S)- 2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound V), N-(phenylsulfonyl)-6-[3-[2-[1-(trifluoromethyl)cyclopropyl]ethoxy]pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound VI), (14S)-8-[3-(2-{dispiro[2.0.2.1]hept-7-yl}ethoxy)-1H-pyrazol-1-yl]-12,12-dimethyl-2λ 6 -thia-3,9,11,18,23-pentazatetracyclo[17.3.1.111,14.05,10]tetracosa-1(22),5,7,9,19(23),20-hexaene-2,2,4-trione (Compound VII), (11R)-6-(2,6-dimethylphenyl)-11-(2-methylpropyl)-12-{spiro[2.3]hex-5-yl}-9-oxa-2λ 6-thia-3,5,12,19-tetraazatricyclo[12.3.1.14,8]nonadecan-1(17),4(19),5,7,14(18),15-hexaene-2,2,13-trione (Compound VIII); N-(phenylsulfonyl)-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound IX) and N-[(6-amino-2-pyridinyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound X). In some embodiments, Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing is administered in the same composition with at least one compound selected from the following: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, a deuterated derivative thereof, and a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, a composition comprising Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing is co-administered with a separate composition comprising at least one compound selected from the following: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, a deuterated derivative thereof, and a pharmaceutically acceptable salt of any of the foregoing.

[0013] Another aspect of the present invention provides a method for treating CFTR-mediated disease cystic fibrosis, the method comprising administering Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing to a patient in need thereof, and optionally further administering one or more additional CFTR modulators selected from the following: ASP-11, disclosed in Journal of Cystic Fibrosis (2018), 17(5), 595-606; and nesolicaftor or PTI-428, disclosed in WO 2016 / 105485. In one embodiment, the additional CFTR modulator is ASP-11. In one embodiment, the additional CFTR modulator comprises PTI-428.

[0014] Another aspect of the present invention provides a method for treating the CFTR-mediated disease cystic fibrosis, the method comprising administering to a patient in need thereof a pharmaceutically acceptable salt of Compound I, a deuterated derivative thereof, or any one of the foregoing, and optionally further administering one or more additional CFTR modulators selected from the following: galicaftor or ABBV-2222, disclosed in U.S. Patent Application Publication No. 2016-0120841; ABBV-3221, disclosed in WO 2018 / 065921; posenacaftor or PTI-801, disclosed in WO 2017 / 062581; ABBV-2851, disclosed in WO 2017 / 009804; GLPG2737, disclosed in U.S. Patent Application Publication No. 2017-0101405; ABBV-3748; ABBV-3903; and ABBV-119.

[0015] In certain embodiments, the pharmaceutical composition of the present invention includes Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing, and may optionally further include at least one compound selected from the following: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, a deuterated derivative thereof, and a pharmaceutically acceptable salt of any one of the foregoing. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 The study design for Part A of the first-in-human (FIH) study of Compound I is provided, and the doses studied are provided.

[0017] Figure 2 The study design for Part B of the FIH study of Compound I is provided, and the doses studied are provided.

[0018] Figure 3 The study design for Part C of the FIH study of Compound I is provided.

[0019] definition

[0020] As used throughout this disclosure, "Compound I" refers to (6R,12R)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol, which can be depicted as having the following structure:

[0021]

[0022] Compound I can be a racemic mixture or an enantiomerically enriched (e.g., >90% ee, >95% ee, >98% ee) mixture of isomers. Compound I or its deuterated derivative can be in the form of a pharmaceutically acceptable salt, solvate and / or hydrate. Compound I and methods for preparing and using Compound I are disclosed in PCT International Application No. PCT / US2021 / 044895, disclosed as WO 2022 / 032068, which is incorporated herein by reference.

[0023] As used herein, "Compound II" refers to (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, which can be depicted by the following structure:

[0024]

[0025] Compound II may be in the form of a pharmaceutically acceptable salt. Compound II and methods of making and using Compound II are disclosed in WO 2010 / 053471, WO 2011 / 119984, WO 2011 / 133751, WO 2011 / 133951 and WO 2015 / 160787, each of which is incorporated herein by reference.

[0026] As used throughout this disclosure, "Compound III" refers to N-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (also known as N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide), which is depicted by the following structure:

[0027]

[0028] Compound III may also be in the form of a pharmaceutically acceptable salt.Compound III and methods of making and using Compound III are disclosed in WO 2006 / 002421, WO 2007 / 079139, WO 2010 / 108162 and WO 2010 / 019239, each of which is incorporated herein by reference.

[0029] In some embodiments, a deuterated derivative of Compound III (Compound III-d) is used in the compositions and methods disclosed herein. The chemical name of Compound III-d is N-(2-(tert-butyl)-5-hydroxy-4-(2-(methyl-d3)propan-2-yl-1,1,1,3,3,3-d6)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide, as depicted in the following structure:

[0030]

[0031] Compound III-d may be in the form of a pharmaceutically acceptable salt. Compound III-d and methods for preparing and using Compound III-d are disclosed in WO 2012 / 158885, WO 2014 / 078842, WO 2019 / 109021, and U.S. Pat. No. 8,865,902, which are incorporated herein by reference.

[0032] As used herein, "Compound IV" refers to 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, which is depicted by the following chemical structure:

[0033]

[0034] Compound IV may be in the form of a pharmaceutically acceptable salt. Compound IV and methods of making and using Compound IV are disclosed in WO 2007 / 056341, WO 2009 / 073757 and WO 2009 / 076142, which are incorporated herein by reference.

[0035] As used herein, "Compound V" refers to N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide, which is depicted by the following chemical structure:

[0036]

[0037] Compound V may be in the form of a pharmaceutically acceptable salt. Compound V and methods of making and using Compound V are disclosed in WO 2018 / 107100 and WO 2019 / 113476, which are incorporated herein by reference.

[0038] As used herein, "Compound VI" refers to N-(benzenesulfonyl)-6-[3-[2-[1-(trifluoromethyl)cyclopropyl]ethoxy]pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide, which is depicted by the following chemical structure:

[0039]

[0040] Compound VI may be in the form of a pharmaceutically acceptable salt. Compound VI and methods for preparing and using Compound VI are disclosed in WO 2018 / 064632 and WO 2019 / 113476, which are incorporated herein by reference.

[0041] As used herein, "Compound VII" refers to (14S)-8-[3-(2-{dispiro[2.0.2.1]hept-7-yl}ethoxy)-1H-pyrazol-1-yl]-12,12-dimethyl-2λ 6 -thia-3,9,11,18,23-pentaazatetracyclo[17.3.1.111,14.05,10]tetracosyl-1(22),5,7,9,19(23),20-hexaene-2,2,4-trione, said compound being depicted by the following chemical structure:

[0042]

[0043] Compound VII may be in the form of a pharmaceutically acceptable salt. Compound VII and methods for preparing and using Compound VII are disclosed in WO 2019 / 161078, WO 2020 / 102346 and WO 2021 / 030554, which are incorporated herein by reference.

[0044] As used herein, "Compound VIII" refers to (11R)-6-(2,6-dimethylphenyl)-11-(2-methylpropyl)-12-{spiro[2.3]hexan-5-yl}-9-oxa-2λ 6 -thia-3,5,12,19-tetraazatricyclo[12.3.1.14,8]nonadecan-1(17),4(19),5,7,14(18),15-hexaene-2,2,13-trione, the compound being depicted by the following chemical structure:

[0045]

[0046] Compound VIII may be in the form of a pharmaceutically acceptable salt. Compound VIII and methods of making and using Compound VIII are disclosed in WO 2020 / 206080, which is incorporated herein by reference.

[0047] As used herein, "Compound IX" refers to N-(benzenesulfonyl)-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide, which is depicted by the following chemical structure:

[0048]

[0049] Compound IX may be in the form of a pharmaceutically acceptable salt. Compound IX and methods of making and using Compound IX are disclosed in WO 2016 / 057572, which is incorporated herein by reference.

[0050] As used herein, "Compound X" refers to N-[(6-amino-2-pyridinyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide, which is depicted by the following chemical structure:

[0051]

[0052] Compound X may be in the form of a pharmaceutically acceptable salt. Compound X and methods of making and using Compound X are disclosed in WO 2016 / 057572, which is incorporated herein by reference.

[0053] As used herein, "CFTR" means cystic fibrosis transmembrane conductance regulator.

[0054] As used herein, "mutation" may refer to a mutation in a CFTR gene or CFTR protein. "CFTR gene mutation" refers to a mutation in a CFTR gene, and "CFTR protein mutation" refers to a mutation in a CFTR protein. Genetic defects or mutations in a gene (i.e., changes in one or more nucleotides) typically result in mutations (i.e., changes in one or more amino acids) or frameshifts (i.e., changes in the reading frame that controls how the CFTR gene is translated into the CFTR protein).

[0055] As used herein, the term "F508del" refers to a mutant CFTR protein lacking the amino acid phenylalanine at position 508, or to a mutant CFTR gene encoding a CFTR protein lacking the amino acid phenylalanine at position 508.

[0056] As used herein, a patient who is "homozygous" for a particular genetic mutation has the same mutation on each allele.

[0057] As used herein, a patient who is "heterozygous" for a particular genetic mutation has that mutation on one allele and a different mutation on the other allele.

[0058] As used herein, the terms "CFTR modulator," "CFTR modulating compound," and "CFTR-modulating agent" refer interchangeably to compounds that directly or indirectly increase the activity of CFTR. CFTR modulators include, but are not limited to, compounds that correct, enhance, stabilize, and / or amplify CFTR.

[0059] As used herein, the term "CFTR corrector" refers to a compound that promotes the processing and transport of CFTR to increase the amount of CFTR at the cell surface. Compound II, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX and Compound X disclosed herein are CFTR correctors.

[0060] As used herein, the term "CFTR potentiator" refers to a compound that increases the channel activity of the CFTR protein located at the cell surface, thereby resulting in enhanced ion transport. Compound III and Compound III-d disclosed herein are CFTR potentiators.

[0061] As used herein, the term "active pharmaceutical ingredient" ("API") or "therapeutic agent" refers to a biologically active compound.

[0062] It should be understood that certain compounds of the present invention may exist as individual stereoisomers or enantiomers and / or mixtures of those stereoisomers or enantiomers. As used in the chemical structures disclosed herein, the "wedge" with respect to stereogenic atoms is or "hash" A bond indicates a chiral center of known absolute stereochemistry (ie, one stereoisomer). As used in the chemical structures disclosed herein, a "wavy" bond to a stereogenic atom indicates a chiral center of unknown absolute stereochemistry (i.e., one stereoisomer). As used in the chemical structures disclosed herein, a "wavy" bond to a double-bonded carbon indicates a mixture of E / Z isomers. As used in the chemical structures disclosed herein, the ("straight") bonds indicate that a mixture (e.g., a racemate or an enrichment) is present. As used herein, the two carbon atoms of a double bond are ("straight") bonds indicate that the double bond has the E / Z stereochemistry as drawn. As used in the chemical structures disclosed herein, (ie, a "wavy" line perpendicular to the "straight" bond of group "A") indicates that group "A" is a substituent whose point of attachment is at the end of the bond terminating at the "wavy" line.

[0063] The terms "patient" and "subject" are used interchangeably and refer to animals including humans.

[0064] The terms "effective dose" and "effective amount" are used interchangeably herein and refer to the amount of a compound that produces the desired effect for which the compound is administered (e.g., improving CF or a symptom of CF, or reducing the severity of a symptom of CF). The exact amount of an effective dose will depend on the purpose of the treatment and will be determined by one skilled in the art using known techniques (see, e.g., Lloyd (1999) The Art, Science and Technology of Pharmaceutical Compounding).

[0065] As used herein, the terms "treatment", "treating" and the like generally mean improving one or more symptoms of CF or its symptoms in a subject or reducing the severity of one or more symptoms of CF or its symptoms. As used herein, "treatment" includes but is not limited to the following: increased growth, increased weight gain, reduced mucus in the lungs, improved pancreatic and / or liver function, reduced chest infection, and / or reduced cough or shortness of breath in a subject. Improvement in any of these symptoms or reduction in their severity can be readily assessed according to standard methods and techniques known in the art.

[0066] As used herein, the term "in combination with" when referring to two or more compounds, agents, or additional APIs means that the two or more compounds, agents, or APIs are administered to the patient before, simultaneously with, or after each other.

[0067] When used in conjunction with the dosage, amount or weight percentage of the ingredients of a composition or dosage form, the terms "about" and "approximately" include a specified dosage, amount or weight percentage value or a range of the dosage, amount or weight percentage that is considered by a person of ordinary skill in the art to provide a pharmacological effect equivalent to that obtained from a specified dosage, amount or weight percentage. The terms "about" and "approximately" may refer to an acceptable error of a specific value determined by a person skilled in the art, which depends in part on how to measure or determine the value. In some embodiments, the terms "about" and "approximately" mean within 15%, 10%, 5%, 4%, 3%, 2%, 1% or 0.5% of a given value or range. In some embodiments, the terms "about" and "approximately" mean within 15% of a given value. In some embodiments, the terms "about" and "approximately" mean within 10% of a given value.

[0068] As used herein, "minimally functional (MF) mutations" refer to CFTR gene mutations that are associated with minimal CFTR function (very low to no functional CFTR protein), and include, for example, mutations associated with severe defects in the ability of the CFTR channel to open and close, known as defective channel gating or "gating mutations"; mutations associated with severe defects in the cellular processing of CFTR and its delivery to the cell surface; mutations associated with no (or minimal) CFTR synthesis; and mutations associated with severe defects in channel transduction.

[0069] As used herein, "deuterated derivative" means the same chemical structure wherein one or more hydrogen atoms are replaced by deuterium atoms.

[0070] As used herein, the term "pharmaceutically acceptable salt" refers to a salt form of a compound of the invention, or a deuterated derivative thereof, wherein the salt is non-toxic. Pharmaceutically acceptable salts of the compounds of the present disclosure include salts derived from suitable inorganic and organic acids and bases. For example, a "free base" form of a compound does not contain ionically bonded salts.

[0071] The phrase "a deuterated derivative or a pharmaceutically acceptable salt thereof" is used interchangeably with "a deuterated derivative thereof or a pharmaceutically acceptable salt of any of the foregoing" when referring to one or more compounds or formulae of the invention. The phrase "a pharmaceutically acceptable salt and a deuterated derivative thereof" is used interchangeably with "a pharmaceutically acceptable salt thereof and a deuterated derivative of any of the foregoing" when referring to one or more compounds or formulae of the invention. These phrases are intended to encompass pharmaceutically acceptable salts of any of the cited compounds, deuterated derivatives of any of the cited compounds, deuterated derivatives of pharmaceutically acceptable salts of any of the cited compounds, and pharmaceutically acceptable salts of deuterated derivatives of any of the cited compounds.

[0072] One of ordinary skill in the art will recognize that when an amount of "a compound or a pharmaceutically acceptable salt thereof" is disclosed, the amount of the pharmaceutically acceptable salt form of the compound is an amount equivalent to the concentration of the free base of the compound. It should be noted that the amounts of the compounds or pharmaceutically acceptable salts thereof disclosed herein are based on their free base form. For example, "100 mg of Compound 1 or a pharmaceutically acceptable salt thereof" or "100 mg of Compound 1 or an equivalent amount of a pharmaceutically acceptable salt thereof" includes 100 mg of Compound 1 and an amount of a pharmaceutically acceptable salt of Compound 1 equivalent to 100 mg of Compound 1.

[0073] Suitable pharmaceutically acceptable salts are, for example, those disclosed in SM Berge et al., J. Pharmaceutical Sciences, 1977, 66, 1-19. For example, Table 1 of the article provides the following pharmaceutically acceptable salts:

[0074] Table 1:

[0075]

[0076]

[0077] Non-limiting examples of pharmaceutically acceptable acid addition salts include: salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid or perchloric acid; salts formed with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid; and salts formed by using other methods used in the art, such as ion exchange. Non-limiting examples of pharmaceutically acceptable salts include adipate, alginate, ascorbic acid, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, and valerate. Pharmaceutically acceptable salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (C 1-4 The present disclosure also contemplates the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Suitable non-limiting examples of alkali metal and alkaline earth metal salts include sodium, lithium, potassium, calcium and magnesium. Other non-limiting examples of pharmaceutically acceptable salts include ammonium, quaternary ammonium, and amine cations formed using counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkyl sulfonates and aryl sulfonates. Other suitable non-limiting examples of pharmaceutically acceptable salts include benzenesulfonates and glucosamine salts. DETAILED DESCRIPTION

[0078] Treatment

[0079] Compound I, its deuterated derivative or any of the pharmaceutically acceptable salts of the foregoing can serve as CFTR regulators, i.e., it regulates the CFTR activity in vivo. Individuals mutated in the gene encoding CFTR can benefit from receiving CFTR regulators. CFTR mutations may affect CFTR amount, i.e., the number of CFTR channels at the cell surface, or they may affect CFTR function, i.e., the functional ability of each channel to open and transport ions. The mutations affecting the amount of CFTR include mutations that cause synthesis defects (class I defects), mutations that cause processing and transport defects (class II defects), mutations that cause CFTR synthesis to reduce (class V defects), and mutations that reduce the surface stability of CFTR (class VI defects). The mutations that affect CFTR function include mutations that cause gating defects (class III defects) and mutations that cause transduction defects (class IV defects). Some CFTR mutations show the characteristics of multiple categories. Some mutations in the CFTR gene cause CF.

[0080] Therefore, in some embodiments, the present invention provides a method for treating cystic fibrosis in a patient, reducing its severity, or treating symptoms thereof, the method comprising administering to the patient an effective amount of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, alone or in combination with another active ingredient such as another CFTR modulator. In some embodiments, the patient has a F508del / minimal function (MF) genotype, a F508del / F508del genotype (homozygous for the F508del mutation), a F508del / gating genotype, or a F508del / residual function (RF) genotype. In some embodiments, the patient is heterozygous and has one F508del mutation. In some embodiments, the patient is homozygous for the N1303K mutation.

[0081] In some embodiments, 5 mg to 100 mg (e.g., 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, or 100 mg) of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing is administered daily. In some embodiments, 7 mg to 90 mg of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing is administered daily. In some embodiments, 10 mg to 80 mg of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing is administered daily. In some embodiments, 10 mg to 40 mg of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing is administered daily. In some embodiments, 30 mg to 60 mg of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any one of the foregoing is administered daily. In some embodiments, 50 mg to 80 mg of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any one of the foregoing is administered daily.

[0082] In some embodiments, about 5 mg to about 100 mg (e.g., about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, or about 100 mg) of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing is administered daily. In some embodiments, about 7 mg to about 90 mg of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing is administered daily. In some embodiments, about 10 mg to about 80 mg of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing is administered daily. In some embodiments, about 10 mg to about 40 mg of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing is administered daily. In some embodiments, about 30 mg to about 60 mg of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing is administered daily. In some embodiments, about 50 mg to about 80 mg of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing is administered daily.

[0083] In some embodiments, about 0.1 mg to about 50 mg (e.g., about 0.1 mg, about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound 1, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing is administered daily. In some embodiments, about 0.25 mg to about 50 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound 1, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing is administered daily. In some embodiments, about 0.25 mg to about 25 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, or about 25 mg) of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing is administered daily. In some embodiments, about 1 mg to about 15 mg (e.g., about 1 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg) of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing is administered daily. In some embodiments, about 1.5 mg to about 14 mg (e.g., about 1.5 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 14 mg) of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing is administered daily. In some embodiments, about 4 mg to about 13 mg (e.g., about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing is administered daily.In some embodiments, about 8 mg to about 13 mg (e.g., about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound 1, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing is administered daily.

[0084] In some embodiments, a total daily dose of about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, about 50 mg to about 80 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, or about 100 mg) of Compound 1, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing is administered in a single dose once a day. In some embodiments, a total daily dose of about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, about 50 mg to about 80 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, or about 100 mg) of Compound 1, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing is administered in two doses.

[0085] In some embodiments, the total daily dose is from about 0.1 mg to about 50 mg (e.g., from about 0.25 mg to about 50 mg, from about 0.25 mg to about 25 mg, from about 1 mg to about 15 mg, from about 1.5 mg to about 14 mg, from about 4 mg to about 13 mg, from about 8 mg to about 13 mg, about 0.1 mg, about 0.25 mg, about 1 mg, about 1.5 mg, about 2.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing) is administered in a single dose. In some embodiments, the total daily dose is from about 0.1 mg to about 50 mg (e.g., from about 0.25 mg to about 50 mg, from about 0.25 mg to about 25 mg, from about 1 mg to about 15 mg, from about 1.5 mg to about 14 mg, from about 4 mg to about 13 mg, from about 8 mg to about 13 mg, about 0.1 mg, about 0.25 mg, about 1 mg, about 1.5 mg, about 2.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9 mg, About 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, about 13 mg, about 14 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg or about 50 mg) of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing is administered in two doses.

[0086] In some embodiments, the patient is heterozygous and has a F508del mutation on one allele and a mutation on the other allele selected from Table 2:

[0087] Table 2: CFTR mutations

[0088]

[0089]

[0090]

[0091] In some embodiments, the present disclosure also relates to methods of treatment using isotopically labeled compounds of the aforementioned compounds or pharmaceutically acceptable salts thereof, wherein the formulas and variables of such compounds and salts are each and independently as described above or in any other embodiment above, with the proviso that one or more atoms are replaced by one or more atoms having an atomic mass or mass number different from the atomic mass or mass number of the atoms normally occurring in nature (isotopically labeled). Examples of commercially available isotopes suitable for use in the present disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, and chlorine, for example, respectively. 2 H. 3 H. 13 C. 14 C. 15 N. 18 O. 17 O. 31 P. 32 P. 35 S. 18 F and 36 Cl.

[0092] Isotope-labeled compounds and salts can be used in a variety of beneficial ways. They can be suitable for use in pharmaceuticals and / or various types of assays, such as substrate tissue distribution assays. For example, tritium ( 3 H) and / or carbon-14 ( 14 C) labeled compounds are particularly useful in various types of assays, such as substrate tissue distribution assays, because of their relatively simple preparation and excellent detectability. 2 H) The labeled compound is useful in therapy and is comparable to non 2 H-labeled compounds have potential therapeutic advantages. In general, deuterium ( 2 H) labeled compounds and salts can have higher metabolic stability due to the kinetic isotope effect described below. Higher metabolic stability is directly converted into increased half-life in vivo or lower dosage, which can be desirable. Isotope-labeled compounds and salts can generally be prepared by replacing non-isotope-labeled reactants with readily available isotope-labeled reactants by the procedures disclosed in the synthetic schemes and related descriptions, in the examples section, and in the preparation section.

[0093] In some embodiments, isotopically labeled compounds and salts are deuterated ( 2 In some specific embodiments, the isotope-labeled compounds and salts are deuterated ( 2H) labeled with one or more hydrogen atoms replaced by deuterium. In chemical structures, deuterium is represented by “ 2 "H" or "D".

[0094] When discovering and developing therapeutic agents, one skilled in the art attempts to optimize pharmacokinetic parameters while retaining desired in vitro properties. It is reasonable to assume that many compounds with poor pharmacokinetic properties are susceptible to oxidative metabolism.

[0095] deuterium( 2 H) labeled compounds and salts can modulate the oxidative metabolism of compounds via the primary kinetic isotope effect. The primary kinetic isotope effect is a change in the rate of a chemical reaction caused by the exchange of isotopic nuclei, which in turn is caused by a change in the ground state energy required to form a covalent bond after this isotope exchange. The exchange of heavier isotopes generally results in a decrease in the ground state energy of a chemical bond, and therefore in a reduction in rate-limiting bond breakage. If bond breakage occurs in or near a saddle point region along the coordinates of a multi-product reaction, the product distribution ratio may change significantly. Explanation: If deuterium is bonded to a carbon atom at a non-exchangeable position, then k M / k D = 2-7 ​​rate differences are typical. For further discussion, see SL Harbeson and RD Tung, Deuterium In Drug Discovery and Development, Ann. Rep. Med. Chem. 2011, 46, 403-417, incorporated herein by reference.

[0096] The concentration of an isotope (e.g., deuterium) incorporated into the isotopically labeled compounds and salts of the present disclosure can be defined by an isotopic enrichment factor. As used herein, the term "isotopic enrichment factor" means the ratio between the isotopic abundance and the natural abundance of a particular isotope. In some embodiments, if a substituent in a compound of the present disclosure is represented as deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).

[0097] Combination therapy

[0098] One aspect disclosed herein provides methods of treating CF and other CFTR-mediated diseases using Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing in combination with at least one additional active pharmaceutical ingredient (API).

[0099] Thus, in some embodiments, the present invention provides a method for treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient, the method comprising administering to the patient about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, alone or in combination with at least one additional active pharmaceutical ingredient, such as a CFTR modulator.

[0100] In some embodiments, the present invention provides a method of treating, lessening the severity of, or treating the symptoms of cystic fibrosis in a patient, the method comprising administering to the patient about 0.1 mg to about 50 mg (e.g., about 0.25 mg to about 50 mg, about 0.25 mg to about 25 mg, about 0.5 mg to about 15 mg, about 1.5 mg to about 14 mg, about 4 mg to about 13 mg, about 8 mg to about 13 mg, about 0.1 mg, about 0.25 mg, about 1 mg, about 1.5 mg, about 2.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg) alone or in combination with at least one additional active pharmaceutical ingredient, such as a CFTR modulator. , about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, about 13 mg, about 14 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0101] In some embodiments, the present invention provides a method for treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient, the method comprising administering to the patient from about 0.1 mg to about 50 mg (e.g., about 0.1 mg, about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, alone or in combination with at least one additional active pharmaceutical ingredient, such as a CFTR modulator.

[0102] In some embodiments, the present invention provides a method for treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient, the method comprising administering to the patient from about 0.25 mg to about 50 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, alone or in combination with at least one additional active pharmaceutical ingredient, such as a CFTR modulator.

[0103] In some embodiments, the present invention provides a method for treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient, the method comprising administering to the patient about 0.25 mg to about 25 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, or about 25 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, alone or in combination with at least one additional active pharmaceutical ingredient, such as a CFTR modulator.

[0104] In some embodiments, the present invention provides a method for treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient, the method comprising administering to the patient about 1 mg to about 15 mg (e.g., about 1 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing, alone or in combination with at least one additional active pharmaceutical ingredient, such as a CFTR modulator.

[0105] In some embodiments, the present invention provides a method for treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient, the method comprising administering to the patient about 1.5 mg to about 14 mg (e.g., about 1.5 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 14 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, alone or in combination with at least one additional active pharmaceutical ingredient, such as a CFTR modulator.

[0106] In some embodiments, the present invention provides a method for treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient, the method comprising administering to the patient about 4 mg to about 13 mg (e.g., about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, alone or in combination with at least one additional active pharmaceutical ingredient, such as a CFTR modulator.

[0107] In some embodiments, the present invention provides a method for treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient, the method comprising administering to the patient about 8 mg to about 13 mg (e.g., about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, alone or in combination with at least one additional active pharmaceutical ingredient, such as a CFTR modulator.

[0108] In some embodiments, the at least one additional API is selected from a mucolytic agent, a bronchodilator, an antibiotic, an anti-infective agent, an anti-inflammatory agent, and a nutritional agent.

[0109] In some embodiments, the additional agent is a mucolytic agent. Exemplary mucolytic agents useful herein include

[0110] In some embodiments, the additional agent is a bronchodilator. Exemplary bronchodilators include albuterol, metaprotenol sulfate, pirbuterolacetate, salmeterol, and tetrabuline sulfate.

[0111] In certain embodiments, the additional therapeutic agent is an antibiotic. Exemplary antibiotics available herein include tobramycin, including tobramycin inhalation powder (TIP); azithromycin; aztreonam, including aerosolized forms of aztreonam; amikacin, including liposomal formulations thereof; ciprofloxacin, including formulations thereof suitable for administration by inhalation; levoflaxacin, including aerosolized formulations thereof; and combinations of two antibiotics, such as fosfomycin and tobramycin.

[0112] In some embodiments, the additional agent is an anti-inflammatory agent, i.e., an agent that can reduce lung inflammation. Exemplary such agents useful herein include ibuprofen, docosahexaenoic acid (DHA), sildenafil, inhaled glutathione, pioglitazone, hydroxychloroquine, and simavastatin.

[0113] In some embodiments, the additional agent is a nutritional agent. Exemplary nutritional agents include pancreatic lipase (a pancreatic enzyme substitute), including or (Previously and glutathione inhalers. In one embodiment, the additional nutritional agent is pancreatic lipase.

[0114] In some embodiments, at least one additional active pharmaceutical ingredient is selected from CFTR modulators. In some embodiments, the CFTR modulator is a CFTR corrector. In some embodiments, the CFTR modulator is a CFTR potentiator enhancer / co-potentiator (e.g., ASP-11). In some embodiments, at least one additional active pharmaceutical ingredient is a CFTR amplifier. In some embodiments, at least one additional active pharmaceutical ingredient is a CFTR read-through agent. In some embodiments, at least one additional active pharmaceutical ingredient is a CFTR nucleic acid therapy.

[0115] In some embodiments, at least one additional active pharmaceutical ingredient is an ENaC inhibitor. In some embodiments, at least one additional active pharmaceutical ingredient is a TMEM16A modulator. In some embodiments, at least one additional active pharmaceutical ingredient is a GPR39 agonist.

[0116] In some embodiments, at least one additional active pharmaceutical ingredient is selected from: (a) Compound II, deuterated derivatives of Compound II, and pharmaceutically acceptable salts of Compound II and its deuterated derivatives; (b) Compound III, deuterated derivatives of Compound III, and pharmaceutically acceptable salts of Compound III and its deuterated derivatives; (c) Compound III-d and pharmaceutically acceptable salts of Compound III-d; (d) Compound IV, deuterated derivatives of Compound IV, and pharmaceutically acceptable salts of Compound IV and its deuterated derivatives; (e) Compound V, deuterated derivatives of Compound V, and pharmaceutically acceptable salts of Compound V and its deuterated derivatives. The invention further comprises a pharmaceutically acceptable salt of compound IX, a deuterated derivative of compound IX, and a pharmaceutically acceptable salt of compound IX and a deuterated derivative thereof; (f) compound VI, a deuterated derivative of compound VI, and a pharmaceutically acceptable salt of compound VI and a deuterated derivative thereof; (g) compound VII, a deuterated derivative of compound VII, and a pharmaceutically acceptable salt of compound VII and a deuterated derivative thereof; (h) compound VIII, a deuterated derivative of compound VIII, and a pharmaceutically acceptable salt of compound VIII and a deuterated derivative thereof; (i) compound IX, a deuterated derivative of compound IX, and a pharmaceutically acceptable salt of compound IX and a deuterated derivative thereof; and (j) compound X, a deuterated derivative of compound X, and a pharmaceutically acceptable salt of compound X and a deuterated derivative thereof. Thus, in some embodiments, the combination therapies provided herein comprise administering Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and at least one compound selected from the group consisting of Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof.

[0117] In some embodiments, the combination therapy provided herein comprises administering: (a) about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) optionally at least one compound selected from the following: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) optionally at least one compound selected from the compounds disclosed in the following documents: WO 2016 / 105485; U.S. Patent Application Publication No. 2016-0120841; U.S. Patent Application Publication No. 2017-0101405; WO 2017 / 009804; WO 2018 / 065921; WO 2017 / 062581; WO 2022 / 076618; WO 2022 / 076620; WO 2022 / 076621; WO 2022 / 076622; WO 2022 / 076624; WO 2022 / 076625; WO 2022 / 076626; WO 2022 / 076627;WO 2022 / 076628;WO 2022 / 076629; U.S. Provisional Patent Application Nos. 63 / 328,097 and 63 / 393,405; Phuan, P.-W. et al. J. Cyst. Fibros. 2018, 17(5), 595-606; Pedemonte, N. et al. Sci. Adv. 2020, 6(8), paper 9669; Phuan, P.-W. et al. Sci. Rep. 2019, 9(1), 17640; Bose, S. et al. Journal of Cystic Fibrosis 2020, 19 Supplement 1, S25-S32; Crawford, DK. Journal of Pharmacology and Experimental Therapeutics (J. Pharmacol. Exp. Ther.) 2020, 374(2), 264-272; Brasell, EJ et al. PLoS One 2019, 14(12), e0223954; Smith, NJ, Solovay, CF, Pharm. Pat. Anal. 2017, 6(4), 179-188; Kunzelmann, K. et al. Frontiers in Pharmacology (Front. Pharmacol.) 2019, 10, 3; or Son, J.-H.et al., European Journal of Medicinal Chemistry (Eur. J. of Med. Chem.), 2020, 112888. .

[0118] In some embodiments, the combination therapies provided herein comprise administration of: (a) about 0.1 mg to about 50 mg (e.g., about 0.1 mg, about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg g, about 47.5 mg or about 50 mg) of Compound I, its deuterated derivative or a pharmaceutically acceptable salt of any of the foregoing; (b) optionally at least one compound selected from the following: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) optionally at least one compound selected from the compounds disclosed in the following documents: WO 2016 / 105485; U.S. Patent Application Publication No. 2016-0120841; U.S. Patent Application Publication No. 2017-0101405; WO 2017 / 009804; WO 2018 / 065921; WO 2017 / 062581; WO 2022 / 076618; WO 2022 / 076620; WO 2022 / 076621; WO 2022 / 076622; WO 2022 / 076624; WO 2022 / 076625; WO 2022 / 076626; WO 2022 / 076627; WO 2022 / 076628; WO 2022 / 076629; U.S. Provisional Patent Application Nos. 63 / 328,097 and 63 / 393,405; Phuan, P.-W. et al. Journal of Cystic Fibrosis 2018, 17(5), 595-606; Pedemonte, N. et al. Science Advances 2020, 6(8), Paper 9669; Phuan, P.-W. et al. Scientific Reports 2019, 9(1), 17640; Bose, S. et al. Journal of Cystic Fibrosis 2020, 19 Supplement 1 , S25-S32; Crawford, DK Journal of Pharmacology and Experimental Therapeutics 2020, 374(2), 264-272; Brasell, EJ et al. Public Library of Science-One 2019, 14(12), e0223954; Smith, NJ, Solovay, CF, Pharmaceutical Patent Analysis 2017, 6(4), 179-188; Kunzelmann, K. et al. Frontiers in Pharmacology 2019, 10, 3; or Son, J.-H.et al., European Journal of Medicinal Chemistry 2020, 112888. .

[0119] In some embodiments, the combination therapies provided herein include administering: (a) about 0.25 mg to about 50 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) optionally at least one compound selected from Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) optionally at least one compound selected from the compounds disclosed in the following documents: WO 2016 / 105485; U.S. Patent Application Publication No. 2016-0120841; U.S. Patent Application Publication No. 2017-0101405; WO 2017 / 009804; WO 2018 / 065921; WO 2017 / 062581; WO 2022 / 076618; WO 2022 / 076620; WO 2022 / 076621; WO 2022 / 076622; WO 2022 / 076624; WO 2022 / 076625; WO 2022 / 076626; WO 2022 / 076627; WO 2022 / 076628; WO 2022 / 076629; U.S. Provisional Patent Application Nos. 63 / 328,097 and 63 / 393,405; Phuan, P.-W. et al. Journal of Cystic Fibrosis 2018, 17(5), 595-606; Pedemonte, N. et al. Science Advances 2020, 6(8), Paper 9669; Phuan, P.-W. et al. Scientific Reports 2019, 9(1), 17640; Bose, S. et al. Journal of Cystic Fibrosis 2020, 19 Supplement 1, S25-S32; Cra Wford, DK, Journal of Pharmacology and Experimental Therapeutics, 2020, 374(2), 264-272; Brasell, EJ, et al., PLoS One, 2019, 14(12), e0223954; Smith, NJ, Solovay, CF, Pharmaceutical Patent Analysis, 2017, 6(4), 179-188; Kunzelmann, K., et al., Frontiers in Pharmacology, 2019, 10, 3; or Son, J.-H., et al., European Journal of Medicinal Chemistry, 2020, 112888.

[0120] In some embodiments, the combination therapy provided herein comprises administering: (a) about 0.25 mg to about 25 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, or about 25 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) optionally at least one compound selected from the following: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) optionally at least one compound selected from the compounds disclosed in the following documents: WO 2016 / 105485; U.S. Patent Application Publication No. 2016-0120841; U.S. Patent Application Publication No. 2017-0101405; WO 2017 / 009804; WO 2018 / 065921; WO 2017 / 062581; WO 2022 / 076618; WO 2022 / 076620; WO 2022 / 076621; WO 2022 / 076622; WO 2022 / 076624; WO 2022 / 076625;WO 2022 / 076626;WO 2022 / 076627;WO 2022 / 076628;WO 2022 / 076629; U.S. Provisional Patent Application Nos. 63 / 328,097 and 63 / 393,405; Phuan, P.-W. et al. Journal of Cystic Fibrosis 2018, 17(5), 595-606; Pedemonte, N. et al. Science Advances 2020, 6(8), Paper 9669; Phuan, P.-W. et al. Scientific Reports 2019, 9(1), 17640; Bose, S. et al. Journal of Cystic Fibrosis 2020, 19 Supplement 1, S25-S32; Cra Wford, DK, Journal of Pharmacology and Experimental Therapeutics, 2020, 374(2), 264-272; Brasell, EJ, et al., PLoS One, 2019, 14(12), e0223954; Smith, NJ, Solovay, CF, Pharmaceutical Patent Analysis, 2017, 6(4), 179-188; Kunzelmann, K., et al., Frontiers in Pharmacology, 2019, 10, 3; or Son, J.-H., et al., European Journal of Medicinal Chemistry, 2020, 112888.

[0121] In some embodiments, the combination therapy provided herein comprises administering: (a) about 1 mg to about 15 mg (e.g., about 1 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) optionally at least one compound selected from the following: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) optionally at least one compound selected from the compounds disclosed in the following documents: WO 2016 / 105485; U.S. Patent Application Publication No. 2016-0120841; U.S. Patent Application Publication No. 2017-0101405; WO 2017 / 009804; WO 2018 / 065921; WO 2017 / 062581; WO 2022 / 076618; WO 2022 / 076620; WO 2022 / 076621; WO 2022 / 076622; WO 2022 / 076624; WO 2022 / 076625; WO 2022 / 076626; WO 2022 / 076627;WO 2022 / 076628;WO 2022 / 076629; U.S. Provisional Patent Application Nos. 63 / 328,097 and 63 / 393,405; Phuan, P.-W. et al. Journal of Cystic Fibrosis 2018, 17(5), 595-606; Pedemonte, N. et al. Science Advances 2020, 6(8), Paper 9669; Phuan, P.-W. et al. Scientific Reports 2019, 9(1), 17640; Bose, S. et al. Journal of Cystic Fibrosis 2020, 19 Supplement 1, S25-S32; Cra Wford, DK, Journal of Pharmacology and Experimental Therapeutics, 2020, 374(2), 264-272; Brasell, EJ, et al., PLoS One, 2019, 14(12), e0223954; Smith, NJ, Solovay, CF, Pharmaceutical Patent Analysis, 2017, 6(4), 179-188; Kunzelmann, K., et al., Frontiers in Pharmacology, 2019, 10, 3; or Son, J.-H., et al., European Journal of Medicinal Chemistry, 2020, 112888.

[0122] In some embodiments, the combination therapy provided herein comprises administering: (a) about 1.5 mg to about 14 mg (e.g., about 1.5 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 14 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) optionally at least one compound selected from the following: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) optionally at least one compound selected from the compounds disclosed in the following documents: WO 2016 / 105485; U.S. Patent Application Publication No. 2016-0120841; U.S. Patent Application Publication No. 2017-0101405; WO 2017 / 009804; WO 2018 / 065921; WO 2017 / 062581; WO 2022 / 076618; WO 2022 / 076620; WO 2022 / 076621; WO 2022 / 076622; WO 2022 / 076624; WO 2022 / 076625; WO 2022 / 076626; WO 2022 / 076627; WO 2022 / 076628; WO 2022 / 076629; U.S. Provisional Patent Application Nos. 63 / 328,097 and 63 / 393,405; Phuan, P.-W. et al. Journal of Cystic Fibrosis 2018, 17(5), 595-606; Pedemonte, N. et al. Science Advances 2020, 6(8), Paper 9669; Phuan, P.-W. et al. Scientific Reports 2019, 9(1), 17640; Bose, S. et al. Journal of Cystic Fibrosis 2020, 19 Supplement 1, S25-S32; Cra Wford, DK, Journal of Pharmacology and Experimental Therapeutics, 2020, 374(2), 264-272; Brasell, EJ, et al., PLoS One, 2019, 14(12), e0223954; Smith, NJ, Solovay, CF, Pharmaceutical Patent Analysis, 2017, 6(4), 179-188; Kunzelmann, K., et al., Frontiers in Pharmacology, 2019, 10, 3; or Son, J.-H., et al., European Journal of Medicinal Chemistry, 2020, 112888.

[0123] In some embodiments, the combination therapy provided herein comprises administering: (a) about 4 mg to about 13 mg (e.g., about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) optionally at least one compound selected from the following: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) optionally at least one compound selected from the compounds disclosed in the following documents: WO 2016 / 105485; U.S. Patent Application Publication No. 2016-0120841; U.S. Patent Application Publication No. 2017-0101405; WO 2017 / 009804; WO 2018 / 065921; WO 2017 / 062581; WO 2022 / 076618; WO 2022 / 076620; WO 2022 / 076621; WO 2022 / 076622; WO 2022 / 076624; WO 2022 / 076625; WO 2022 / 076626; WO 2022 / 076627; WO 2022 / 076628; WO2022 / 076629; U.S. Provisional Patent Application Nos. 63 / 328,097 and 63 / 393,405; Phuan, P.-W. et al. Journal of Cystic Fibrosis 2018, 17(5), 595-606; Pedemonte, N. et al. Science Advances 2020, 6(8), Paper 9669; Phuan, P.-W. et al. Scientific Reports 2019, 9(1), 17640; Bose, S. et al. Journal of Cystic Fibrosis 2020, 19 Supplement 1, S25- S32; Crawford, DK, Journal of Pharmacology and Experimental Therapeutics, 2020, 374(2), 264-272; Brasell, EJ, et al., PLoS ONE, 2019, 14(12), e0223954; Smith, NJ, Solovay, CF, Pharmaceutical Patent Analysis, 2017, 6(4), 179-188; Kunzelmann, K., et al., Frontiers in Pharmacology, 2019, 10, 3; or Son, J.-H., et al., European Journal of Medicinal Chemistry, 2020, 112888.

[0124] In some embodiments, the combination therapy provided herein comprises administering: (a) about 8 mg to about 13 mg (e.g., about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) optionally at least one compound selected from the following: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) optionally at least one compound selected from the compounds disclosed in the following documents: WO 2016 / 105485; U.S. Patent Application Publication No. 2016-0120841; U.S. Patent Application Publication No. 2017-0101405; WO 2017 / 009804; WO 2018 / 065921; WO 2017 / 062581; WO 2022 / 076618; WO 2022 / 076620; WO 2022 / 076621; WO 2022 / 076622; WO 2022 / 076624; WO 2022 / 076625; WO 2022 / 076626; WO 2022 / 076627; WO 2022 / 076628; WO 2022 / 076629; U.S. Provisional Patent Application Nos. 63 / 328,097 and 63 / 393,405; Phuan, P.-W. et al. Journal of Cystic Fibrosis 2018, 17(5), 595-606; Pedemonte, N. et al. Science Advances 2020, 6(8), Paper 9669; Phuan, P.-W. et al. Scientific Reports 2019, 9(1), 17640; Bose, S. et al. Journal of Cystic Fibrosis 2020, 19 Supplement 1, S25-S32; Cra Wford, DK, Journal of Pharmacology and Experimental Therapeutics, 2020, 374(2), 264-272; Brasell, EJ, et al., PLoS One, 2019, 14(12), e0223954; Smith, NJ, Solovay, CF, Pharmaceutical Patent Analysis, 2017, 6(4), 179-188; Kunzelmann, K., et al., Frontiers in Pharmacology, 2019, 10, 3; or Son, J.-H., et al., European Journal of Medicinal Chemistry, 2020, 112888.

[0125] In some embodiments, the combination therapies provided herein include administering: (a) about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) optionally at least one compound selected from Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) optionally at least one compound selected from PTI-428, ASP-11, ABBV-2222, ABBV-2851, GLPG2737, ABBV-3221, ABBV-3748, ABBV-3903, ABBV-119, FDL-169, ARN5562, ARN21586, ARN22081, ARN22652, ARN23765, ARN23766, PTI-801, FDL-176, PTI-808, GLPG1837 / ABBV-974, GLPG2451 / ABBV-2451, QBW251 (Icenticaftor), GLPG3067 / ABBV-3067 ( Navocaftor), ABBV-191, ELX-02, MRT5005, Lunar-CF, RCT223, amiloride, ETD001, CF552, GS-9411, GS-5737, P-1037 (VX-371), P-1055 (VX-551), AZD5634, SPX-101, Ionis-ENaC-2.5Rx, BI 1265162, ARO-ENaC1001, ETD002, and DS-1039.

[0126] In some embodiments, the combination therapies provided herein comprise administering: (a) about 0.1 mg to about 50 mg (e.g., about 0.1 mg, about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg). mg) of Compound I, its deuterated derivative or a pharmaceutically acceptable salt of any one of the foregoing; (b) optionally at least one compound selected from the following: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) optionally at least one compound selected from the following: PTI-428, ASP-11, ABBV-2222, ABBV-2851, G LPG2737, ABBV-3221, ABBV-3748, ABBV-3903, ABBV-119, FDL-169, ARN5562, ARN21586, ARN22081, ARN22652, ARN23 765, ARN23766, PTI-801, FDL-176, PTI-808, GLPG1837 / ABBV-974, GLPG2451 / ABBV-2451, QBW251 (Ethankato), GLPG3067 / ABBV-3067 (Navocato), ABBV-191, ELX-02, MRT5005, Lunar-CF, RCT223, Amiloride, ETD001, CF552, GS-9411, GS-5737, P-1037 (VX-371), P-1055 (VX-551), AZD5634, SPX-101, Ionis-ENaC-2.5Rx, BI1265162, ARO-ENaC1001, ETD002, and DS-1039.

[0127] In some embodiments, the combination therapies provided herein comprise administration of: (a) about 0.25 mg to about 50 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) optionally at least one compound selected from the following: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) optionally at least one compound selected from the following: PTI-428, ASP-11, ABBV-2222, ABBV-2851, GLPG 2737, ABBV-3221, ABBV-3748, ABBV-3903, ABBV-119, FDL-169, ARN5562, ARN21586, ARN22081, ARN22652, ARN2376 5. ARN23766, PTI-801, FDL-176, PTI-808, GLPG1837 / ABBV-974, GLPG2451 / ABBV-2451, QBW251 (Ethankato), GLPG3067 / A BBV-3067 (Navocato), ABBV-191, ELX-02, MRT5005, Lunar-CF, RCT223, Amiloride, ETD001, CF552, GS-9411, GS-5737, P-1037 (VX-371), P-1055 (VX-551), AZD5634, SPX-101, Ionis-ENaC-2.5Rx, BI1265162, ARO-ENaC1001, ETD002, and DS-1039.

[0128] In some embodiments, the combination therapies provided herein include administering: (a) about 0.25 mg to about 25 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, or about 25 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) optionally at least one compound selected from Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) optionally at least one compound selected from PTI-428, ASP-11, ABBV-2222, ABBV-2851, GLPG2737, ABBV-3221, ABBV-3748, ABBV-3903, ABBV-119, FDL-169, ARN5562, ARN21586, ARN22081, ARN22652, ARN23765, ARN23766, PTI-801, FDL-176, PTI-808, GLPG1837 / ABBV-974, GLPG2451 / ABBV-2451, QBW251 (Isenkato), GLPG3067 / ABBV-3067 (Navokato), ABB V-191, ELX-02, MRT5005, Lunar-CF, RCT223, amiloride, ETD001, CF552, GS-9411, GS-5737, P-1037 (VX-371), P-1055 (VX-551), AZD5634, SPX-101, Ionis-ENaC-2.5Rx, BI1265162, ARO-ENaC1001, ETD002, and DS-1039.

[0129] In some embodiments, the combination therapy provided herein comprises administering: (a) about 1 mg to about 15 mg (e.g., about 1 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) optionally at least one compound selected from the group consisting of Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) optionally at least one compound selected from the group consisting of PTI-428, ASP-11, ABBV-2222, ABBV-2851, GLPG2737, ABBV-3221, ABBV-3748, ABBV-3903 、ABBV-119、FDL-169、ARN5562、ARN21586、ARN22081、ARN22652、ARN23765、ARN23766、PTI-801、FDL-176、PTI-808、GLPG1837 / ABBV-974、GLPG2451 / ABBV-2451、QBW251(Ethankato)、GLPG3067 / ABBV-3067 (Navocato), ABBV-191, ELX-02, MRT5005, Lunar-CF, RCT223, Amiloride, ETD001, CF552, GS-9411, GS-5737, P-1037 (VX-371), P-1055 (VX-551), AZD5634, SPX-101, Ionis-ENaC-2.5Rx, BI 1265162, ARO-ENaC1001, ETD002, and DS-1039.

[0130] In some embodiments, the combination therapy provided herein comprises administering: (a) about 1.5 mg to about 14 mg (e.g., about 1.5 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 14 mg) of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing; (b) optionally at least one compound selected from the following: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) optionally at least one compound selected from the following: PTI-428, ASP-11, ABBV-2222, ABBV-2851, GLPG2737, ABBV-3221, ABBV-3748, ABBV-39 03, ABBV-119, FDL-169, ARN5562, ARN21586, ARN22081, ARN22652, ARN23765, ARN23766, PTI-801, FDL-176, PTI-808, GLPG1837 / ABBV-974, GLPG2451 / ABBV-2451, QBW251 (Ethankato), GLPG3067 / ABBV-3067 (Navocato), ABBV-191, ELX-02, MRT5005, Lunar-CF, RCT223, Amiloride, ETD001, CF552, GS-9411, GS-5737, P-1037 (VX-371), P-1055 (VX-551), AZD5634, SPX-101, Ionis-ENaC-2.5Rx, BI 1265162, ARO-ENaC1001, ETD002, and DS-1039.

[0131] In some embodiments, the combination therapy provided herein comprises administering: (a) about 4 mg to about 13 mg (e.g., about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) optionally at least one compound selected from Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) optionally at least one compound selected from PTI-428, ASP-11, ABBV-2222, ABBV-2851, G LPG2737, ABBV-3221, ABBV-3748, ABBV-3903, ABBV-119, FDL-169, ARN5562, ARN21586, ARN22081, ARN22 652, ARN23765, ARN23766, PTI-801, FDL-176, PTI-808, GLPG1837 / ABBV-974, GLPG2451 / ABBV-2451, QBW2 51 (Isencatto), GLPG3067 / ABBV-3067 (Navcatto), ABBV-191, ELX-02, MRT5005, Lunar-CF, RCT223, Amiloride, ETD001, CF552, GS-9411, GS-5737, P-1037 (VX-371), P-1055 (VX-551), AZD5634, SPX-101, Ionis-ENaC-2.5Rx, BI 1265162, ARO-ENaC1001, ETD002, and DS-1039.

[0132] In some embodiments, the combination therapy provided herein comprises administering: (a) about 8 mg to about 13 mg (e.g., about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) optionally at least one compound selected from the group consisting of Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) optionally at least one compound selected from the group consisting of PTI-428, ASP-11, ABBV-2222, ABBV-2851, GLPG2737, ABBV-3221, ABBV-3 748, ABBV-3903, ABBV-119, FDL-169, ARN5562, ARN21586, ARN22081, ARN22652, ARN23765, ARN23766, PTI-801, FDL-176, PTI-808, GLPG1837 / ABBV-974, GLPG2451 / ABBV-2451, QBW251 (Esenkato), GLP G3067 / ABBV-3067 (Navocato), ABBV-191, ELX-02, MRT5005, Lunar-CF, RCT223, Amiloride, ETD001, CF552, GS-9411, GS-5737, P-1037 (VX-371), P-1055 (VX-551), AZD5634, SPX-101, Ionis-ENaC-2.5Rx, BI 1265162, ARO-ENaC1001, ETD002, and DS-1039.

[0133] In some embodiments, about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing is administered in combination with at least one compound selected from Compound II and a pharmaceutically acceptable salt and deuterated derivative thereof. In some embodiments, about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing is administered in combination with at least one compound selected from Compound III and a pharmaceutically acceptable salt and deuterated derivative thereof. In some embodiments, about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing is administered in combination with at least one compound selected from Compound III-d and a pharmaceutically acceptable salt thereof. In some embodiments, about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing is administered in combination with at least one compound selected from Compound IV and a deuterated derivative and a pharmaceutically acceptable salt thereof. In some embodiments, about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing is administered in combination with at least one compound selected from Compound V and deuterated derivatives and pharmaceutically acceptable salts thereof. In some embodiments, about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing is administered in combination with at least one compound selected from Compound VI and deuterated derivatives and pharmaceutically acceptable salts thereof.In some embodiments, about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing is administered in combination with at least one compound selected from Compound VII and its deuterated derivatives and pharmaceutically acceptable salts. In some embodiments, about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing is administered in combination with at least one compound selected from Compound VIII and its deuterated derivatives and pharmaceutically acceptable salts. In some embodiments, about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing is administered in combination with at least one compound selected from Compound IX and deuterated derivatives and pharmaceutically acceptable salts thereof. In some embodiments, about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing is administered in combination with at least one compound selected from Compound X and deuterated derivatives and pharmaceutically acceptable salts thereof.

[0134] In some embodiments, about 0.1 mg to about 50 mg (e.g., about 0.25 mg to about 50 mg, about 0.25 mg to about 25 mg, about 0.5 mg to about 15 mg, about 1.5 mg to about 14 mg, about 4 mg to about 13 mg, about 8 mg to about 13 mg, about 0.1 mg, about 0.25 mg, about 1 mg, about 1.5 mg, about 2.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10. 5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, about 13 mg, about 14 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing is administered in combination with at least one compound selected from Compound II and a pharmaceutically acceptable salt and deuterated derivative thereof. In some embodiments, about 0.1 mg to about 50 mg (e.g., about 0.25 mg to about 50 mg, about 0.25 mg to about 25 mg, about 0.5 mg to about 15 mg, about 1.5 mg to about 14 mg, about 4 mg to about 13 mg, about 8 mg to about 13 mg, about 0.1 mg, about 0.25 mg, about 1 mg, about 1.5 mg, about 2.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10. 5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, about 13 mg, about 14 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing is administered in combination with at least one compound selected from Compound IV and a deuterated derivative and a pharmaceutically acceptable salt thereof.In some embodiments, about 0.1 mg to about 50 mg (e.g., about 0.25 mg to about 25 mg, about 0.5 mg to about 15 mg, about 1.5 mg to about 14 mg, about 4 mg to about 13 mg, about 8 mg to about 13 mg, about 0.1 mg, about 0.25 mg, about 1 mg, about 1.5 mg, about 2.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11.5 mg, about 12.5 mg, about 13.5 mg, about 14.5 mg, about 15.5 mg, about 16.5 mg, about 17.5 mg, about 18.5 mg, about 19.5 mg, about 20.5 mg, about 21.5 mg, about 22.5 mg, about 23.5 mg, about 24.5 mg, about 25.5 mg, about 26.5 mg, about 27.5 mg, about 28.5 mg, about 29.5 mg, about 30.5 mg, about 31.5 mg, about 32.5 mg, about 33.5 mg, about 34.5 mg, about 35.5 mg, about 36.5 mg, about 37.5 mg, about 38.5 mg, about 39.5 mg, about 39.5 mg, about 40.5 mg, about 41.5 mg, about 42.5 mg, about 43.5 mg, about 44.5 mg, about 45.5 mg, about 46.5 mg, about 47.5 mg, about 48 1 mg, about 11.5 mg, about 12 mg, about 12.5 mg, about 13 mg, about 14 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing is administered in combination with at least one compound selected from Compound V and a deuterated derivative and a pharmaceutically acceptable salt thereof. In some embodiments, about 0.1 mg to about 50 mg (e.g., about 0.25 mg to about 50 mg, about 0.25 mg to about 25 mg, about 0.5 mg to about 15 mg, about 1.5 mg to about 14 mg, about 4 mg to about 13 mg, about 8 mg to about 13 mg, about 0.1 mg, about 0.25 mg, about 1 mg, about 1.5 mg, about 2.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10. 5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, about 13 mg, about 14 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, is administered in combination with at least one compound selected from Compound VI and a deuterated derivative and a pharmaceutically acceptable salt thereof.In some embodiments, about 0.1 mg to about 50 mg (e.g., about 0.25 mg to about 50 mg, about 0.25 mg to about 25 mg, about 0.5 mg to about 15 mg, about 1.5 mg to about 14 mg, about 4 mg to about 13 mg, about 8 mg to about 13 mg, about 0.1 mg, about 0.25 mg, about 1 mg, about 1.5 mg, about 2.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10. 5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, about 13 mg, about 14 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, is administered in combination with at least one compound selected from Compound VII and its deuterated derivatives and pharmaceutically acceptable salts. In some embodiments, about 0.1 mg to about 50 mg (e.g., about 0.25 mg to about 50 mg, about 0.25 mg to about 25 mg, about 0.5 mg to about 15 mg, about 1.5 mg to about 14 mg, about 4 mg to about 13 mg, about 8 mg to about 13 mg, about 0.1 mg, about 0.25 mg, about 1 mg, about 1.5 mg, about 2.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 In some embodiments, the present invention relates to an oral administration of about 1% to about 5% (about 20% to about 15% of Compound I), a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing (about 1% to about 5% of Compound VIII), about 1% to about 2% (about 15% to about 25% of Compound I), a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing) in combination with at least one compound selected from Compound VIII and a deuterated derivative thereof and a pharmaceutically acceptable salt thereof.In some embodiments, about 0.1 mg to about 50 mg (e.g., about 0.25 mg to about 50 mg, about 0.25 mg to about 25 mg, about 0.5 mg to about 15 mg, about 1.5 mg to about 14 mg, about 4 mg to about 13 mg, about 8 mg to about 13 mg, about 0.1 mg, about 0.25 mg, about 1 mg, about 1.5 mg, about 2.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10. about 5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, about 13 mg, about 14 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, is administered in combination with at least one compound selected from Compound IX and a deuterated derivative and a pharmaceutically acceptable salt thereof. In some embodiments, about 0.1 mg to about 50 mg (e.g., about 0.25 mg to about 50 mg, about 0.25 mg to about 25 mg, about 0.5 mg to about 15 mg, about 1.5 mg to about 14 mg, about 4 mg to about 13 mg, about 8 mg to about 13 mg, about 0.1 mg, about 0.25 mg, about 1 mg, about 1.5 mg, about 2.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10 .5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, about 13 mg, about 14 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, is administered in combination with at least one compound selected from Compound X and a deuterated derivative and a pharmaceutically acceptable salt thereof.

[0135] In some embodiments, about 0.1 mg to about 50 mg (e.g., about 0.25 mg to about 50 mg, about 0.25 mg to about 25 mg, about 0.5 mg to about 15 mg, about 1.5 mg to about 14 mg, about 4 mg to about 13 mg, about 8 mg to about 13 mg, about 0.1 mg, about 0.25 mg, about 1 mg, about 1.5 mg, about 2.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10. 5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, about 13 mg, about 14 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing is administered in combination with at least one compound selected from Compound III and a pharmaceutically acceptable salt and deuterated derivative thereof. In some embodiments, about 0.1 mg to about 50 mg (e.g., about 0.25 mg to about 50 mg, about 0.25 mg to about 25 mg, about 0.5 mg to about 15 mg, about 1.5 mg to about 14 mg, about 4 mg to about 13 mg, about 8 mg to about 13 mg, about 0.1 mg, about 0.25 mg, about 1 mg, about 1.5 mg, about 2.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 21 mg, about 22 mg, about 23 mg, about 24 mg, about 25 mg, about 26 mg, about 27 mg, about 28 mg, about 29 mg, about 30 mg, about 31 mg, about 32 mg, about 33 mg, about 34 mg, about 35 mg, about 36 mg, about 37 mg, about 38 mg, about 39 mg, about 40 mg, about 41 mg, about 42 mg, about 43 mg, about 44 mg 0.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, about 13 mg, about 14 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg or about 50 mg) of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any one of the foregoing is administered in combination with at least one compound selected from Compound III-d and a pharmaceutically acceptable salt thereof.

[0136] In some embodiments, about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing is administered in combination with at least one compound selected from Compound II and deuterated derivatives and pharmaceutically acceptable salts thereof, and at least one compound selected from Compound V and pharmaceutically acceptable salts and deuterated derivatives thereof. In some embodiments, about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing is administered in combination with at least one compound selected from Compound II and deuterated derivatives and pharmaceutically acceptable salts thereof, and at least one compound selected from Compound VI and deuterated derivatives and pharmaceutically acceptable salts thereof. In some embodiments, about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing is administered in combination with at least one compound selected from Compound II and its deuterated derivatives and pharmaceutically acceptable salts, and at least one compound selected from Compound VII and its deuterated derivatives and pharmaceutically acceptable salts. In some embodiments, about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing is administered in combination with at least one compound selected from Compound II and its deuterated derivatives and pharmaceutically acceptable salts, and at least one compound selected from Compound VIII and its deuterated derivatives and pharmaceutically acceptable salts.

[0137] In some embodiments, about 0.1 mg to about 50 mg (e.g., about 0.25 mg to about 50 mg, about 0.25 mg to about 25 mg, about 0.5 mg to about 15 mg, about 1.5 mg to about 14 mg, about 4 mg to about 13 mg, about 8 mg to about 13 mg, about 0.1 mg, about 0.25 mg, about 1 mg, about 1.5 mg, about 2.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg) is added. g, about 12 mg, about 12.5 mg, about 13 mg, about 14 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing, in combination with at least one compound selected from Compound II and its deuterated derivatives and pharmaceutically acceptable salts, and at least one compound selected from Compound V and its pharmaceutically acceptable salts and deuterated derivatives. In some embodiments, about 0.1 mg to about 50 mg (e.g., about 0.25 mg to about 50 mg, about 0.25 mg to about 25 mg, about 0.5 mg to about 15 mg, about 1.5 mg to about 14 mg, about 4 mg to about 13 mg, about 8 mg to about 13 mg, about 0.1 mg, about 0.25 mg, about 1 mg, about 1.5 mg, about 2.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg) is added. , about 12 mg, about 12.5 mg, about 13 mg, about 14 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, in combination with at least one compound selected from Compound II and its deuterated derivatives and pharmaceutically acceptable salts and at least one compound selected from Compound VI and its deuterated derivatives and pharmaceutically acceptable salts.In some embodiments, about 0.1 mg to about 50 mg (e.g., about 0.25 mg to about 50 mg, about 0.25 mg to about 25 mg, about 0.5 mg to about 15 mg, about 1.5 mg to about 14 mg, about 4 mg to about 13 mg, about 8 mg to about 13 mg, about 0.1 mg, about 0.25 mg, about 1 mg, about 1.5 mg, about 2.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg) is added. , about 12 mg, about 12.5 mg, about 13 mg, about 14 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg or about 50 mg) of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing, in combination with at least one compound selected from Compound II and its deuterated derivatives and pharmaceutically acceptable salts, and at least one compound selected from Compound VII and its deuterated derivatives and pharmaceutically acceptable salts. In some embodiments, about 0.1 mg to about 50 mg (e.g., about 0.25 mg to about 50 mg, about 0.25 mg to about 25 mg, about 0.5 mg to about 15 mg, about 1.5 mg to about 14 mg, about 4 mg to about 13 mg, about 8 mg to about 13 mg, about 0.1 mg, about 0.25 mg, about 1 mg, about 1.5 mg, about 2.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, about 13 mg, about 14 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg or about 50 mg) of Compound I, its deuterated derivative or a pharmaceutically acceptable salt of any of the foregoing, in combination with at least one compound selected from Compound II and its deuterated derivatives and pharmaceutically acceptable salts and at least one compound selected from Compound VIII and its deuterated derivatives and pharmaceutically acceptable salts.

[0138] Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any one of the foregoing, and each of the compounds selected from the following can be independently administered once a day, twice a day, or three times a day: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof.

[0139] In some embodiments, Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing is administered once a day. In some embodiments, Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing is administered twice a day. In some embodiments, Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing, and at least one compound selected from the following are administered once a day: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof. In some embodiments, Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing, and at least one compound selected from the following are administered twice a day: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof. In some embodiments, Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing, and at least one compound selected from Compound II and a deuterated derivative thereof and a pharmaceutically acceptable salt thereof are administered once a day. In some embodiments, Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing, and at least one compound selected from Compound II and a deuterated derivative thereof and a pharmaceutically acceptable salt thereof are administered twice a day.

[0140] Compound I, its deuterated derivatives, or pharmaceutically acceptable salts of any of the foregoing, and additional therapeutic agents can be administered in a single pharmaceutical composition or in separate pharmaceutical compositions. Thus, (a) about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, its deuterated derivatives, or pharmaceutically acceptable salts of any of the foregoing, and (b) a compound selected from the following can be administered in a single pharmaceutical composition comprising (a) and (b), or in separate pharmaceutical compositions: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof, wherein the first composition comprises (a) and the second composition comprises (b). Such pharmaceutical compositions can be administered once a day or multiple times a day, such as twice or three times a day. As used herein, the phrase a given amount of API (e.g., Compound 1, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing) is administered once or twice a day or daily means that the given amount is administered by daily dosing, which may occur once or twice a day.

[0141] Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing and the additional therapeutic agent can be administered in a single pharmaceutical composition or in separate pharmaceutical compositions. Thus, (a) from about 0.1 mg to about 50 mg (e.g., from about 0.25 mg to about 50 mg, from about 0.25 mg to about 25 mg, from about 0.5 mg to about 15 mg, from about 1.5 mg to about 14 mg, from about 4 mg to about 13 mg, from about 8 mg to about 13 mg, about 0.1 mg, about 0.25 mg, about 1 mg, about 1.5 mg, about 2.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, about 13 mg, about 14 mg, about 15 mg, about 17.5 mg, about 2 0mg, about 22.5mg, about 25mg, about 27.5mg, about 30mg, about 32.5mg, about 35mg, about 37.5mg, about 40mg, about 42.5mg, about 45mg, about 47.5mg or about 50mg) of Compound I, its deuterated derivative or a pharmaceutically acceptable salt of any of the foregoing and (b) a compound selected from the following can be administered as a single pharmaceutical composition including (a) and (b), or as a separate pharmaceutical composition: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X and deuterated derivatives and pharmaceutically acceptable salts thereof, wherein the first composition includes (a) and the second composition includes (b). Such pharmaceutical compositions can be administered once a day or multiple times a day, such as twice or three times a day. As used herein, the phrase a given amount of API (e.g., Compound 1, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing) is administered once or twice a day or daily means that the given amount is administered by daily dosing, which may occur once or twice a day.

[0142] In some embodiments, about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing is administered in a first pharmaceutical composition; and at least one compound selected from the following is administered in a second pharmaceutical composition: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof.

[0143] In some embodiments, about 0.1 mg to about 50 mg (e.g., about 0.25 mg to about 50 mg, about 0.25 mg to about 25 mg, about 0.5 mg to about 15 mg, about 1.5 mg to about 14 mg, about 4 mg to about 13 mg, about 8 mg to about 13 mg, about 0.1 mg, about 0.25 mg, about 1 mg, about 1.5 mg, about 2.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, about 13 mg, about 1 4 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg or about 50 mg) of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing is administered as a first pharmaceutical composition; and at least one compound selected from the following is administered as a second pharmaceutical composition: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X and deuterated derivatives and pharmaceutically acceptable salts thereof.

[0144] Any suitable pharmaceutical composition known in the art can be used for Compound I, Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof. Some exemplary pharmaceutical compositions for Compound II and pharmaceutically acceptable salts thereof can be found in WO 2011 / 119984 and WO 2014 / 014841, which are incorporated herein by reference. Some exemplary pharmaceutical compositions for compound III and its pharmaceutically acceptable salts can be found in WO 2007 / 134279, WO 2010 / 019239, WO 2011 / 019413, WO 2012 / 027731 and WO 2013 / 130669, and some exemplary pharmaceutical compositions for compound III-d and its pharmaceutically acceptable salts can be found in US 8,865,902, US 9,181,192, US 9,512,079, WO 2017 / 053455 and WO 2018 / 080591, all of which are incorporated herein by reference. Some exemplary pharmaceutical compositions for compound IV and its pharmaceutically acceptable salts can be found in WO 2010 / 037066, WO 2011 / 127421 and WO 2014 / 071122, which are incorporated herein by reference. Some exemplary pharmaceutical compositions for Compound V and pharmaceutically acceptable salts thereof can be found in WO 2019 / 152940, which is incorporated herein by reference. Some exemplary pharmaceutical compositions for Compound VI and pharmaceutically acceptable salts thereof can be found in WO 2019 / 079760, which is incorporated herein by reference.

[0145] Pharmaceutical composition

[0146] Another aspect of the present invention provides a pharmaceutical composition comprising Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing, and at least one pharmaceutically acceptable carrier.

[0147] In some embodiments, the present disclosure provides a pharmaceutical composition comprising: (a) about 5 mg to about 100 mg of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any one of the foregoing; and (b) at least one pharmaceutically acceptable carrier. In some embodiments, the present disclosure provides a pharmaceutical composition comprising: (a) about 7 mg to about 90 mg of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any one of the foregoing; and (b) at least one pharmaceutically acceptable carrier. In some embodiments, the present disclosure provides a pharmaceutical composition comprising: (a) about 10 mg to about 80 mg of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any one of the foregoing; and (b) at least one pharmaceutically acceptable carrier. In some embodiments, the present disclosure provides a pharmaceutical composition comprising: (a) about 10 mg to about 40 mg of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any one of the foregoing; and (b) at least one pharmaceutically acceptable carrier. In some embodiments, the present disclosure provides a pharmaceutical composition comprising: (a) about 30 mg to about 60 mg of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (b) at least one pharmaceutically acceptable carrier. In some embodiments, the present disclosure provides a pharmaceutical composition comprising: (a) about 50 mg to about 80 mg of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (b) at least one pharmaceutically acceptable carrier.

[0148] In some embodiments, the present disclosure provides a pharmaceutical composition comprising: (a) about 0.1 mg to about 50 mg (e.g., about 0.1 mg, about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (b) at least one pharmaceutically acceptable carrier.

[0149] In some embodiments, the present disclosure provides a pharmaceutical composition comprising: (a) about 0.25 mg to about 50 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (b) at least one pharmaceutically acceptable carrier.

[0150] In some embodiments, the present disclosure provides a pharmaceutical composition comprising: (a) about 0.25 mg to about 25 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, or about 25 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (b) at least one pharmaceutically acceptable carrier.

[0151] In some embodiments, the present disclosure provides a pharmaceutical composition comprising: (a) about 1 mg to about 15 mg (e.g., about 1 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (b) at least one pharmaceutically acceptable carrier.

[0152] In some embodiments, the present disclosure provides a pharmaceutical composition comprising: (a) about 1.5 mg to about 14 mg (e.g., about 1.5 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 14 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (b) at least one pharmaceutically acceptable carrier.

[0153] In some embodiments, the present disclosure provides a pharmaceutical composition comprising: (a) about 4 mg to about 13 mg (e.g., about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (b) at least one pharmaceutically acceptable carrier.

[0154] In some embodiments, the present disclosure provides a pharmaceutical composition comprising: (a) about 8 mg to about 13 mg (e.g., about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (b) at least one pharmaceutically acceptable carrier.

[0155] In some embodiments, the present invention provides a pharmaceutical composition comprising: about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and optionally at least one additional active pharmaceutical ingredient. In some embodiments, at least one additional active pharmaceutical ingredient is a CFTR modulator. In some embodiments, at least one additional active pharmaceutical ingredient is a CFTR corrector. In some embodiments, at least one additional active pharmaceutical ingredient is a CFTR potentiator. In some embodiments, at least one additional active pharmaceutical ingredient is a compound that enhances CFTR potentiation, i.e., a CFTR potentiator enhancer / co-potentiator. In some embodiments, at least one additional active pharmaceutical ingredient is a CFTR amplifier. In some embodiments, at least one additional active pharmaceutical ingredient is a CFTR read-through agent. In some embodiments, at least one additional active pharmaceutical ingredient is a CFTR nucleic acid therapy. In some embodiments, at least one additional active pharmaceutical ingredient is an ENaC inhibitor. In some embodiments, at least one additional active pharmaceutical ingredient is a TMEM16A modulator. In some embodiments, at least one additional active pharmaceutical ingredient is a GPR39 agonist. In some embodiments, the pharmaceutical composition comprises: Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and at least one additional active pharmaceutical ingredient as a CFTR corrector. In some embodiments, the pharmaceutical composition comprises: Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and at least two additional active pharmaceutical ingredients, each of which is a CFTR corrector.

[0156] In some embodiments, the present invention provides a pharmaceutical composition comprising: about 0.1 mg to about 50 mg (e.g., about 0.25 mg to about 50 mg, about 0.25 mg to about 25 mg, about 0.5 mg to about 15 mg, about 1.5 mg to about 14 mg, about 4 mg to about 13 mg, about 8 mg to about 13 mg, about 0.1 mg, about 0.25 mg, about 1 mg, about 1.5 mg, about 2.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, about 13 mg, about 14 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and optionally at least one additional active pharmaceutical ingredient. In some embodiments, at least one additional active pharmaceutical ingredient is a CFTR modulator. In some embodiments, at least one additional active pharmaceutical ingredient is a CFTR corrector. In some embodiments, at least one additional active pharmaceutical ingredient is a CFTR potentiator. In some embodiments, at least one additional active pharmaceutical ingredient is a compound that enhances CFTR synergism, i.e., a CFTR synergist enhancer / co-potentiator. In some embodiments, at least one additional active pharmaceutical ingredient is a CFTR amplifier. In some embodiments, at least one additional active pharmaceutical ingredient is a CFTR read-through agent. In some embodiments, at least one additional active pharmaceutical ingredient is a CFTR nucleic acid therapy. In some embodiments, at least one additional active pharmaceutical ingredient is an ENaC inhibitor. In some embodiments, at least one additional active pharmaceutical ingredient is a TMEM16A modulator. In some embodiments, at least one additional active pharmaceutical ingredient is a GPR39 agonist. In some embodiments, the pharmaceutical composition includes: Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and at least one additional active pharmaceutical ingredient as a CFTR corrector. In some embodiments, the pharmaceutical composition includes: Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and at least two additional active pharmaceutical ingredients, each of which is a CFTR corrector.

[0157] In some embodiments, the present invention provides a pharmaceutical composition comprising: (a) about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) at least one compound selected from the group consisting of Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the present invention provides a pharmaceutical composition comprising: (a) Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; (b) at least two compounds selected from the group consisting of Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) at least one pharmaceutically acceptable carrier.

[0158] In some embodiments, the present invention provides a pharmaceutical composition comprising: (a) about 0.1 mg to about 50 mg (e.g., about 0.1 mg, about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) at least one compound selected from the group consisting of Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the present invention provides a pharmaceutical composition comprising: (a) about 0.1 mg to about 50 mg (e.g., about 0.1 mg, about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) at least two compounds selected from the group consisting of Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) at least one pharmaceutically acceptable carrier.

[0159] In some embodiments, the present invention provides a pharmaceutical composition comprising: (a) about 0.25 mg to about 50 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) at least one compound selected from the group consisting of Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the present invention provides a pharmaceutical composition comprising: (a) about 0.25 mg to about 50 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) at least two compounds selected from the group consisting of Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) at least one pharmaceutically acceptable carrier.

[0160] In some embodiments, the present invention provides a pharmaceutical composition comprising: (a) about 0.25 mg to about 25 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, or about 25 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) at least one compound selected from the group consisting of Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the present invention provides a pharmaceutical composition comprising: (a) about 0.25 mg to about 25 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, or about 25 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) at least two compounds selected from the group consisting of Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) at least one pharmaceutically acceptable carrier.

[0161] In some embodiments, the present invention provides a pharmaceutical composition comprising: (a) about 1 mg to about 15 mg (e.g., about 1 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg) of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing; (b) at least one compound selected from the following: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the present invention provides a pharmaceutical composition comprising: (a) about 1 mg to about 15 mg (e.g., about 1 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg) of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing; (b) at least two compounds selected from the following: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) at least one pharmaceutically acceptable carrier.

[0162] In some embodiments, the present invention provides a pharmaceutical composition comprising: (a) about 1.5 mg to about 14 mg (e.g., about 1.5 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 14 mg) of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing; (b) at least one compound selected from the following: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the present invention provides a pharmaceutical composition comprising: (a) about 1.5 mg to about 14 mg (e.g., about 1.5 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 14 mg) of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing; (b) at least two compounds selected from the following: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) at least one pharmaceutically acceptable carrier.

[0163] In some embodiments, the present invention provides a pharmaceutical composition comprising: (a) about 4 mg to about 13 mg (e.g., about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) at least one compound selected from the group consisting of Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the present invention provides a pharmaceutical composition comprising: (a) about 4 mg to about 13 mg (e.g., about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) at least two compounds selected from the group consisting of Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) at least one pharmaceutically acceptable carrier.

[0164] In some embodiments, the present invention provides a pharmaceutical composition comprising: (a) about 8 mg to about 13 mg (e.g., about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) at least one compound selected from the group consisting of Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the present invention provides a pharmaceutical composition comprising: (a) about 8 mg to about 13 mg (e.g., about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) at least two compounds selected from the group consisting of Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) at least one pharmaceutically acceptable carrier.

[0165] In some embodiments, the present invention provides a pharmaceutical composition comprising: (a) about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) at least one compound selected from Compound II and its deuterated derivatives and pharmaceutically acceptable salts; and (c) at least one pharmaceutically acceptable carrier.

[0166] In some embodiments, the present invention provides a pharmaceutical composition comprising: (a) about 0.1 mg to about 50 mg (e.g., about 0.1 mg, about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) at least one compound selected from Compound II and a deuterated derivative thereof and a pharmaceutically acceptable salt thereof; and (c) at least one pharmaceutically acceptable carrier.

[0167] In some embodiments, the present disclosure provides a pharmaceutical composition comprising: (a) about 0.25 mg to about 50 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) at least one compound selected from Compound II and a deuterated derivative thereof and a pharmaceutically acceptable salt thereof; and (c) at least one pharmaceutically acceptable carrier.

[0168] In some embodiments, the present invention provides a pharmaceutical composition comprising: (a) about 0.25 mg to about 25 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, or about 25 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) at least one compound selected from Compound II and a deuterated derivative thereof and a pharmaceutically acceptable salt thereof; and (c) at least one pharmaceutically acceptable carrier.

[0169] In some embodiments, the present invention provides a pharmaceutical composition comprising: (a) about 1 mg to about 15 mg (e.g., about 1 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg) of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing; (b) at least one compound selected from Compound II and its deuterated derivatives and pharmaceutically acceptable salts; and (c) at least one pharmaceutically acceptable carrier.

[0170] In some embodiments, the present invention provides a pharmaceutical composition comprising: (a) about 1.5 mg to about 14 mg (e.g., about 1.5 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 14 mg) of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing; (b) at least one compound selected from Compound II and its deuterated derivatives and pharmaceutically acceptable salts; and (c) at least one pharmaceutically acceptable carrier.

[0171] In some embodiments, the present disclosure provides a pharmaceutical composition comprising: (a) about 4 mg to about 13 mg (e.g., about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) at least one compound selected from Compound II and a deuterated derivative thereof and a pharmaceutically acceptable salt thereof; and (c) at least one pharmaceutically acceptable carrier.

[0172] In some embodiments, the present invention provides a pharmaceutical composition comprising: (a) about 8 mg to about 13 mg (e.g., about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) at least one compound selected from Compound II and a deuterated derivative thereof and a pharmaceutically acceptable salt thereof; and (c) at least one pharmaceutically acceptable carrier.

[0173] In some embodiments, the present disclosure provides a pharmaceutical composition comprising: (a) about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) at least one compound selected from Compound II and a deuterated derivative thereof and a pharmaceutically acceptable salt thereof; (c) at least one compound selected from the following: Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X and a deuterated derivative thereof and a pharmaceutically acceptable salt thereof; and (d) at least one pharmaceutically acceptable carrier.

[0174] In some embodiments, the present disclosure provides a pharmaceutical composition comprising: (a) about 0.1 mg to about 50 mg (e.g., about 0.1 mg, about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 46 mg, about 48 mg, about 49 mg, about 50 mg, about 51 mg, about 52 mg, about 53 mg, about 54 mg, about 55 mg, about 56 mg, about 57 mg, about 58 mg, about 59 mg, about 60 mg, about 61 mg, about 62 mg, about 63 mg, about 64 mg, about 65 mg, about 67 mg, about 68 mg, about 69 mg, about 70 mg, about 71 mg, about 72 mg, about 73 mg, about 74 mg, about 75 mg, about 76 mg, about 77 mg, about 78 mg, about 79 mg, about 80 mg, about 81 mg, about 82 mg, about 83 mg, about 84 mg, about 85 mg, about 86 mg, about 87 (a) about 7.5 mg or about 50 mg) of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any one of the foregoing; (b) at least one compound selected from Compound II and its deuterated derivatives and pharmaceutically acceptable salts; (c) at least one compound selected from the following: Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and their deuterated derivatives and pharmaceutically acceptable salts; and (d) at least one pharmaceutically acceptable carrier.

[0175] In some embodiments, the present disclosure provides a pharmaceutical composition comprising: (a) about 0.25 mg to about 50 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg); (b) at least one compound selected from Compound II and its deuterated derivatives and pharmaceutically acceptable salts; (c) at least one compound selected from the following: Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X and its deuterated derivatives and pharmaceutically acceptable salts; and (d) at least one pharmaceutically acceptable carrier.

[0176] In some embodiments, the present disclosure provides a pharmaceutical composition comprising: (a) about 0.25 mg to about 25 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, or about 25 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) at least one compound selected from Compound II and a deuterated derivative thereof and a pharmaceutically acceptable salt thereof; (c) at least one compound selected from the following: Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and a deuterated derivative thereof and a pharmaceutically acceptable salt thereof; and (d) at least one pharmaceutically acceptable carrier.

[0177] In some embodiments, the present disclosure provides a pharmaceutical composition comprising: (a) about 1 mg to about 15 mg (e.g., about 1 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg) of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing; (b) at least one compound selected from Compound II and its deuterated derivatives and pharmaceutically acceptable salts; (c) at least one compound selected from the following: Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X and its deuterated derivatives and pharmaceutically acceptable salts; and (d) at least one pharmaceutically acceptable carrier.

[0178] In some embodiments, the present disclosure provides a pharmaceutical composition comprising: (a) about 1.5 mg to about 14 mg (e.g., about 1.5 mg, about 4 mg, about 6.5 mg, about 9 mg, about 11.5 mg, or about 14 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) at least one compound selected from Compound II and a deuterated derivative thereof and a pharmaceutically acceptable salt thereof; (c) at least one compound selected from the following: Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and a deuterated derivative thereof and a pharmaceutically acceptable salt thereof; and (d) at least one pharmaceutically acceptable carrier.

[0179] In some embodiments, the present disclosure provides a pharmaceutical composition comprising: (a) about 4 mg to about 13 mg (e.g., about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) at least one compound selected from Compound II and a deuterated derivative thereof and a pharmaceutically acceptable salt thereof; (c) at least one compound selected from the following: Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and a deuterated derivative thereof and a pharmaceutically acceptable salt thereof; and (d) at least one pharmaceutically acceptable carrier.

[0180] In some embodiments, the present disclosure provides a pharmaceutical composition comprising: (a) about 8 mg to about 13 mg (e.g., about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) at least one compound selected from Compound II and a deuterated derivative thereof and a pharmaceutically acceptable salt thereof; (c) at least one compound selected from the following: Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and a deuterated derivative thereof and a pharmaceutically acceptable salt thereof; and (d) at least one pharmaceutically acceptable carrier.

[0181] In some embodiments, the pharmaceutical compositions provided herein include: (a) about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) optionally at least one compound selected from the following: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; (c) optionally at least one compound selected from the compounds disclosed in the following documents: WO 2016 / 105485; U.S. Patent Application Publication No. 2016-0120841; U.S. Patent Application Publication No. 2017-0101405; WO 2017 / 009804; WO 2018 / 065921; WO 2017 / 062581; WO 2022 / 076618; WO 2022 / 076620; WO 2022 / 076621; WO 2022 / 076622; WO 2022 / 076624; WO 2022 / 076625; WO 2022 / 076626; WO 2022 / 076627;WO 2022 / 076628;WO 2022 / 076629; U.S. Provisional Patent Application Nos. 63 / 328,097 and 63 / 393,405; Phuan, P.-W. et al. Journal of Cystic Fibrosis 2018, 17(5), 595-606; Pedemonte, N. et al. Science Advances 2020, 6(8), Paper 9669; Phuan, P.-W. et al. Scientific Reports 2019, 9(1), 17640; Bose, S. et al. Journal of Cystic Fibrosis 2020, 19 Supplement 1, S25-S32; Crawford, D.K. Pharmaceutical Review 2019, 19(6), S25-S32; Journal of Pharmacology and Experimental Therapeutics 2020, 374(2), 264-272; Brasell, EJ et al. Public Library of Science-One 2019, 14(12), e0223954; Smith, NJ, Solovay, CF, Pharmaceutical Patent Analysis 2017, 6(4), 179-188; Kunzelmann, K. et al., Frontiers in Pharmacology 2019, 10, 3; or Son, J.-H. et al., European Journal of Medicinal Chemistry 2020, 112888; and (d) at least one pharmaceutically acceptable carrier.

[0182] In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.1 mg to about 50 mg (e.g., about 0.1 mg, about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg); g, about 47.5 mg or about 50 mg) of Compound I, its deuterated derivative or a pharmaceutically acceptable salt of any of the foregoing; (b) optionally at least one compound selected from the following: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X and deuterated derivatives and pharmaceutically acceptable salts thereof; (c) optionally at least one compound selected from the compounds disclosed in the following documents: WO 2016 / 105485; U.S. Patent Application Publication No. 2016-0120841; U.S. Patent Application Publication No. 2017-0101405; WO 2017 / 009804; WO 2018 / 065921; WO 2017 / 062581; WO 2022 / 076618; WO 2022 / 076620; WO 2022 / 076621; WO 2022 / 076622; WO 2022 / 076624; WO 2022 / 076625; WO 2022 / 076626; WO 2022 / 076627; WO 2022 / 076628; WO 2022 / 076629; U.S. Provisional Patent Application Nos. 63 / 328,097 and 63 / 393,405; Phuan, P.-W. et al. Journal of Cystic Fibrosis 2018, 17(5), 595-606; Pedemonte, N. et al. Science Advances 2020, 6(8), Paper 9669; Phuan, P.-W. et al. Scientific Reports 2019, 9(1), 17640; Bose, S. et al. Journal of Cystic Fibrosis 2020, 19 Supplement 1 , S25-S32; Crawford, DK Journal of Pharmacology and Experimental Therapeutics 2020, 374(2), 264-272; Brasell, EJ et al. Public Library of Science-One 2019, 14(12), e0223954; Smith, NJ, Solovay, CF, Pharmaceutical Patent Analysis 2017, 6(4), 179-188; Kunzelmann, K. et al. Frontiers in Pharmacology 2019, 10, 3; or Son, J.-H.et al., European Journal of Medicinal Chemistry 2020, 112888; and (d) at least one pharmaceutically acceptable carrier. .

[0183] In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.25 mg to about 50 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) optionally at least one compound selected from the following: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; (c) optionally at least one compound selected from the compounds disclosed in the following documents: WO 2016 / 105485; U.S. Patent Application Publication No. 2016-0120841; U.S. Patent Application Publication No. 2017-0101405; WO 2017 / 009804; WO 2018 / 065921; WO 2017 / 062581; WO 2022 / 076618; WO 2022 / 076620; WO 2022 / 076621; WO 2022 / 076622; WO 2022 / 076624; WO 2022 / 076625; WO 2022 / 076626; WO 2022 / 076627; WO 2022 / 076628; WO 2022 / 076629; U.S. Provisional Patent Application Nos. 63 / 328,097 and 63 / 393,405; Phuan, P.-W. et al. Journal of Cystic Fibrosis 2018, 17(5), 595-606; Pedemonte, N. et al. Science Advances 2020, 6(8), Paper 9669; Phuan, P.-W. et al. Scientific Reports 2019, 9(1), 17640; Bose, S. et al. Journal of Cystic Fibrosis 2020, 19 Supplement 1 , S25-S32; Crawford, DK Journal of Pharmacology and Experimental Therapeutics 2020, 374(2), 264-272; Brasell, EJ et al. Public Library of Science-One 2019, 14(12), e0223954; Smith, NJ, Solovay, CF, Pharmaceutical Patent Analysis 2017, 6(4), 179-188; Kunzelmann, K. et al. Frontiers in Pharmacology 2019, 10, 3; or Son, J.-H.et al., European Journal of Medicinal Chemistry 2020, 112888; and (d) at least one pharmaceutically acceptable carrier. .

[0184] In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.25 mg to about 25 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, or about 25 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) optionally at least one compound selected from the following: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; (c) optionally at least one compound selected from the compounds disclosed in the following documents: WO 2016 / 105485; U.S. Patent Application Publication No. 2016-0120841; U.S. Patent Application Publication No. 2017-0101405; WO 2017 / 009804; WO 2018 / 065921; WO 2017 / 062581; WO 2022 / 076618; WO 2022 / 076620; WO 2022 / 076621; WO 2022 / 076622; WO 2022 / 076624; WO 2022 / 076625; WO 2022 / 076626; WO 2022 / 076627; WO 2022 / 076628; WO 2022 / 076629; U.S. Provisional Patent Application Nos. 63 / 328,097 and 63 / 393,405; Phuan, P.-W. et al. Journal of Cystic Fibrosis 2018, 17(5), 595-606; Pedemonte, N. et al. Science Advances 2020, 6(8), Paper 9669; Phuan, P.-W. et al. Scientific Reports 2019, 9(1), 17640; Bose, S. et al. Journal of Cystic Fibrosis 2020, 19 Supplement 1, S25-S32; Crawford, D.K. Pharmaceutical Review 2019, 19(6), S25-S32; Journal of Pharmacology and Experimental Therapeutics 2020, 374(2), 264-272; Brasell, EJ et al. Public Library of Science-One 2019, 14(12), e0223954; Smith, NJ, Solovay, CF, Pharmaceutical Patent Analysis 2017, 6(4), 179-188; Kunzelmann, K. et al., Frontiers in Pharmacology 2019, 10, 3; or Son, J.-H. et al., European Journal of Medicinal Chemistry 2020, 112888; and (d) at least one pharmaceutically acceptable carrier.

[0185] In some embodiments, the pharmaceutical compositions provided herein include: (a) about 1 mg to about 15 mg (e.g., about 1 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) optionally at least one compound selected from the following: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; (c) optionally at least one compound selected from the compounds disclosed in the following documents: WO 2016 / 105485; U.S. Patent Application Publication No. 2016-0120841; U.S. Patent Application Publication No. 2017-0101405; WO 2017 / 009804; WO 2018 / 065921; WO 2017 / 062581; WO 2022 / 076618; WO 2022 / 076620; WO 2022 / 076621; WO 2022 / 076622; WO 2022 / 076624; WO 2022 / 076625; WO 2022 / 076626; WO 2022 / 076627; WO 2022 / 076628;WO 2022 / 076629; U.S. Provisional Patent Application Nos. 63 / 328,097 and 63 / 393,405; Phuan, P.-W. et al. Journal of Cystic Fibrosis 2018, 17(5), 595-606; Pedemonte, N. et al. Science Advances 2020, 6(8), Paper 9669; Phuan, P.-W. et al. Scientific Reports 2019, 9(1), 17640; Bose, S. et al. Journal of Cystic Fibrosis 2020, 19 Supplement 1, S25-S32; Crawford, D.K. Pharmaceutical Review 2019, 19(6), S25-S32; Journal of Pharmacology and Experimental Therapeutics 2020, 374(2), 264-272; Brasell, EJ et al. Public Library of Science-One 2019, 14(12), e0223954; Smith, NJ, Solovay, CF, Pharmaceutical Patent Analysis 2017, 6(4), 179-188; Kunzelmann, K. et al., Frontiers in Pharmacology 2019, 10, 3; or Son, J.-H. et al., European Journal of Medicinal Chemistry 2020, 112888; and (d) at least one pharmaceutically acceptable carrier.

[0186] In some embodiments, the pharmaceutical compositions provided herein include: (a) about 1.5 mg to about 14 mg (e.g., about 1.5 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 14 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) optionally at least one compound selected from the following: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; (c) optionally at least one compound selected from the compounds disclosed in the following documents: WO 2016 / 105485; U.S. Patent Application Publication No. 2016-0120841; U.S. Patent Application Publication No. 2017-0101405; WO 2017 / 009804; WO 2018 / 065921; WO 2017 / 062581; WO 2022 / 076618; WO 2022 / 076620; WO 2022 / 076621; WO 2022 / 076622; WO 2022 / 076624; WO 2022 / 076625; WO 2022 / 076626; WO 2022 / 076627;WO 2022 / 076628;WO 2022 / 076629; U.S. Provisional Patent Application Nos. 63 / 328,097 and 63 / 393,405; Phuan, P.-W. et al. Journal of Cystic Fibrosis 2018, 17(5), 595-606; Pedemonte, N. et al. Science Advances 2020, 6(8), Paper 9669; Phuan, P.-W. et al. Scientific Reports 2019, 9(1), 17640; Bose, S. et al. Journal of Cystic Fibrosis 2020, 19 Supplement 1, S25-S32; Crawford, D.K. Pharmaceutical Review 2019, 19(6), S25-S32; Journal of Pharmacology and Experimental Therapeutics 2020, 374(2), 264-272; Brasell, EJ et al. Public Library of Science-One 2019, 14(12), e0223954; Smith, NJ, Solovay, CF, Pharmaceutical Patent Analysis 2017, 6(4), 179-188; Kunzelmann, K. et al., Frontiers in Pharmacology 2019, 10, 3; or Son, J.-H. et al., European Journal of Medicinal Chemistry 2020, 112888; and (d) at least one pharmaceutically acceptable carrier.

[0187] In some embodiments, the pharmaceutical compositions provided herein include: (a) about 4 mg to about 13 mg (e.g., about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) optionally at least one compound selected from the following: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; (c) optionally at least one compound selected from the compounds disclosed in the following documents: WO 2016 / 105485; U.S. Patent Application Publication No. 2016-0120841; U.S. Patent Application Publication No. 2017-0101405; WO 2017 / 009804; WO 2018 / 065921; WO 2017 / 062581; WO 2022 / 076618; WO 2022 / 076620; WO 2022 / 076621; WO 2022 / 076622; WO 2022 / 076624; WO 2022 / 076625; WO 2022 / 076626; WO 2022 / 076627; WO 2022 / 076628; WO 2022 / 076629; U.S. Provisional Patent Application Nos. 63 / 328,097 and 63 / 393,405; Phuan, P.-W. et al. Journal of Cystic Fibrosis 2018, 17(5), 595-606; Pedemonte, N. et al. Science Advances 2020, 6(8), Paper 9669; Phuan, P.-W. et al. Scientific Reports 2019, 9(1), 17640; Bose, S. et al. Journal of Cystic Fibrosis 2020, 19 Supplement 1, S25-S32; Crawford, D.K. Pharmaceutical Review 2019, 19(6), S25-S32; Journal of Pharmacology and Experimental Therapeutics 2020, 374(2), 264-272; Brasell, EJ et al. Public Library of Science-One 2019, 14(12), e0223954; Smith, NJ, Solovay, CF, Pharmaceutical Patent Analysis 2017, 6(4), 179-188; Kunzelmann, K. et al., Frontiers in Pharmacology 2019, 10, 3; or Son, J.-H. et al., European Journal of Medicinal Chemistry 2020, 112888; and (d) at least one pharmaceutically acceptable carrier.

[0188] In some embodiments, the pharmaceutical compositions provided herein include: (a) about 8 mg to about 13 mg (e.g., about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) optionally at least one compound selected from the following: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; (c) optionally at least one compound selected from the compounds disclosed in the following documents: WO 2016 / 105485; U.S. Patent Application Publication No. 2016-0120841; U.S. Patent Application Publication No. 2017-0101405; WO 2017 / 009804; WO 2018 / 065921; WO 2017 / 062581; WO 2022 / 076618; WO 2022 / 076620; WO 2022 / 076621; WO 2022 / 076622; WO 2022 / 076624; WO 2022 / 076625; WO 2022 / 076626;WO 2022 / 076627;WO 2022 / 076628;WO 2022 / 076629; U.S. Provisional Patent Application Nos. 63 / 328,097 and 63 / 393,405; Phuan, P.-W. et al. Journal of Cystic Fibrosis 2018, 17(5), 595-606; Pedemonte, N. et al. Science Advances 2020, 6(8), Paper 9669; Phuan, P.-W. et al. Scientific Reports 2019, 9(1), 17640; Bose, S. et al. Journal of Cystic Fibrosis 2020, 19 Supplement 1, S25-S32; Crawford, D.K. Pharmaceutical Review 2019, 19(6), S25-S32; Journal of Pharmacology and Experimental Therapeutics 2020, 374(2), 264-272; Brasell, EJ et al. Public Library of Science-One 2019, 14(12), e0223954; Smith, NJ, Solovay, CF, Pharmaceutical Patent Analysis 2017, 6(4), 179-188; Kunzelmann, K. et al., Frontiers in Pharmacology 2019, 10, 3; or Son, J.-H. et al., European Journal of Medicinal Chemistry 2020, 112888; and (d) at least one pharmaceutically acceptable carrier.

[0189] In some embodiments, the pharmaceutical compositions provided herein include: (a) about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) optionally at least one compound selected from the following: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; (c) optionally at least one compound selected from the following: PTI-428, ASP-11, ABBV-2222, ABBV-2851, GLPG2737, ABBV-3221, ABBV-3748, ABBV-4 BV-3903, ABBV-119, FDL-169, ARN5562, ARN21586, ARN22081, ARN22652, ARN23765, ARN23766, PTI-801, FDL-176, PTI-808, GLPG1837 / ABBV-974, GLPG2451 / ABBV-2451, QBW251 (Ethankato), GLPG30 67 / ABBV-3067 (Navocato), ABBV-191, ELX-02, MRT5005, Lunar-CF, RCT223, amiloride, ETD001, CF552, GS-9411, GS-5737, P-1037 (VX-371), P-1055 (VX-551), AZD5634, SPX-101, Ionis-ENaC-2.5Rx, BI 1265162, ARO-ENaC1001, ETD002 and DS-1039; and (d) at least one pharmaceutically acceptable carrier.

[0190] In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.1 mg to about 50 mg (e.g., about 0.1 mg, about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of (b) optionally at least one compound selected from the group consisting of Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; (c) optionally at least one compound selected from the group consisting of PTI-428, ASP-11, ABBV-2222, ABBV-2851, GLPG2737, ABB V-3221, ABBV-3748, ABBV-3903, ABBV-119, FDL-169, ARN5562, ARN21586, ARN22081, ARN22652, ARN23765, ARN23766, PTI-801, FDL-176, PTI-808, GLPG1837 / ABBV-974, GLPG2451 / ABBV-2451, QBW251 (Isenkato), GLPG3067 / ABBV-3067 (Navokato) , ABBV-191, ELX-02, MRT5005, Lunar-CF, RCT223, amiloride, ETD001, CF552, GS-9411, GS-5737, P-1037 (VX-371), P-1055 (VX-551), AZD5634, SPX-101, Ionis-ENaC-2.5Rx, BI1265162, ARO-ENaC1001, ETD002 and DS-1039; and (d) at least one pharmaceutically acceptable carrier.

[0191] In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.25 mg to about 50 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg); g or about 50 mg) of Compound I, its deuterated derivative or a pharmaceutically acceptable salt of any of the foregoing; (b) optionally at least one compound selected from the following: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X and deuterated derivatives and pharmaceutically acceptable salts thereof; (c) optionally at least one compound selected from the following: PTI-428, ASP-11, ABBV-22 22. ABBV-2851, GLPG2737, ABBV-3221, ABBV-3748, ABBV-3903, ABBV-119, FDL-169, ARN5562, ARN21586, ARN2 2081, ARN22652, ARN23765, ARN23766, PTI-801, FDL-176, PTI-808, GLPG1837 / ABBV-974, GLPG2451 / ABBV-24 51, QBW251 (Isencatol), GLPG3067 / ABBV-3067 (Navocatol), ABBV-191, ELX-02, MRT5005, Lunar-CF, RCT223, amiloride, ETD001, CF552, GS-9411, GS-5737, P-1037 (VX-371), P-1055 (VX-551), AZD5634, SPX-101, Ionis-ENaC-2.5Rx, BI 1265162, ARO-ENaC1001, ETD002 and DS-1039; and (d) at least one pharmaceutically acceptable carrier.

[0192] In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.25 mg to about 25 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, or about 25 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) optionally at least one compound selected from the following: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; (c) optionally at least one compound selected from the following: PTI-428, ASP-11, ABBV-2222, ABBV-2851, GLPG2737, ABBV-3221, ABB V-3748, ABBV-3903, ABBV-119, FDL-169, ARN5562, ARN21586, ARN22081, ARN22652, ARN23765, ARN23766, PTI-801, FDL-176, PTI-808, GLPG1837 / ABBV-974, GLPG2451 / ABBV-2451, QBW251 (Ethankato), G LPG3067 / ABBV-3067 (Navocato), ABBV-191, ELX-02, MRT5005, Lunar-CF, RCT223, amiloride, ETD001, CF552, GS-9411, GS-5737, P-1037 (VX-371), P-1055 (VX-551), AZD5634, SPX-101, Ionis-ENaC-2.5Rx, BI 1265162, ARO-ENaC1001, ETD002 and DS-1039; and (d) at least one pharmaceutically acceptable carrier.

[0193] In some embodiments, the pharmaceutical compositions provided herein include: (a) about 1 mg to about 15 mg (e.g., about 1 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg) of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing; (b) optionally at least one compound selected from the following: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; (c) optionally at least one compound selected from the following: PTI-428, ASP-11, ABBV-2222, ABBV-2851, GLPG2737, ABBV-3221, ABBV-3748, ABBV-3903, ABBV-119, FDL-169, ARN5562, ARN21586, ARN22081, ARN22652, ARN23765, ARN23766, PTI-801, FDL-176, PTI-808, GLPG1837 / ABBV-974, GLPG2451 / ABBV-2451, QBW251 (Esenkato), GLPG3067 / A BBV-3067 (Navocato), ABBV-191, ELX-02, MRT5005, Lunar-CF, RCT223, amiloride, ETD001, CF552, GS-9411, GS-5737, P-1037 (VX-371), P-1055 (VX-551), AZD5634, SPX-101, Ionis-ENaC-2.5Rx, BI 1265162, ARO-ENaC1001, ETD002 and DS-1039; and (d) at least one pharmaceutically acceptable carrier.

[0194] In some embodiments, the pharmaceutical compositions provided herein include: (a) about 1.5 mg to about 14 mg (e.g., about 1.5 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 14 mg) of Compound I, its deuterated derivative, or a pharmaceutically acceptable salt of any of the foregoing; (b) optionally at least one compound selected from the following: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; (c) optionally at least one compound selected from the following: PTI-428, ASP-11, ABBV-2222, ABBV-2851, GLPG2737, ABBV-3221, ABBV-3748, ABBV-390 3. ABBV-119, FDL-169, ARN5562, ARN21586, ARN22081, ARN22652, ARN23765, ARN23766, PTI-801, FDL-176, PTI-808, GLPG1837 / ABBV-974, GLPG2451 / ABBV-2451, QBW251 (Esenkato), GLPG3067 / ABBV-3067 (Navocator), ABBV-191, ELX-02, MRT5005, Lunar-CF, RCT223, amiloride, ETD001, CF552, GS-9411, GS-5737, P-1037 (VX-371), P-1055 (VX-551), AZD5634, SPX-101, Ionis-ENaC-2.5Rx, BI 1265162, ARO-ENaC1001, ETD002 and DS-1039; and (d) at least one pharmaceutically acceptable carrier.

[0195] In some embodiments, the pharmaceutical compositions provided herein include: (a) about 4 mg to about 13 mg (e.g., about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) optionally at least one compound selected from the group consisting of Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; (c) optionally at least one compound selected from the group consisting of PTI-428, ASP-11, ABBV-2222, ABBV-2851, GL PG2737, ABBV-3221, ABBV-3748, ABBV-3903, ABBV-119, FDL-169, ARN5562, ARN21586, ARN22081, ARN226 52. ARN23765, ARN23766, PTI-801, FDL-176, PTI-808, GLPG1837 / ABBV-974, GLPG2451 / ABBV-2451, QBW2 51 (Esencato), GLPG3067 / ABBV-3067 (Navocato), ABBV-191, ELX-02, MRT5005, Lunar-CF, RCT223, amiloride, ETD001, CF552, GS-9411, GS-5737, P-1037 (VX-371), P-1055 (VX-551), AZD5634, SPX-101, Ionis-ENaC-2.5Rx, BI 1265162, ARO-ENaC1001, ETD002 and DS-1039; and (d) at least one pharmaceutically acceptable carrier.

[0196] In some embodiments, the pharmaceutical compositions provided herein include: (a) about 8 mg to about 13 mg (e.g., about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) optionally at least one compound selected from the following: Compound II, Compound III, Compound III-d, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; (c) optionally at least one compound selected from the following: PTI-428, ASP-11, ABBV-2222, ABBV-2851, GLPG2737, ABBV-3221, ABBV-37 48. ABBV-3903, ABBV-119, FDL-169, ARN5562, ARN21586, ARN22081, ARN22652, ARN23765, ARN23766, PTI-801, FDL-176, PTI-808, GLPG1837 / ABBV-974, GLPG2451 / ABBV-2451, QBW251 (Esenkato), GLP G3067 / ABBV-3067 (Navocato), ABBV-191, ELX-02, MRT5005, Lunar-CF, RCT223, amiloride, ETD001, CF552, GS-9411, GS-5737, P-1037 (VX-371), P-1055 (VX-551), AZD5634, SPX-101, Ionis-ENaC-2.5Rx, BI 1265162, ARO-ENaC1001, ETD002 and DS-1039; and (d) at least one pharmaceutically acceptable carrier.

[0197] In some embodiments, the pharmaceutical compositions provided herein include: (a) about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound III, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound III-d, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound IV, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound V, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier.In some embodiments, the pharmaceutical compositions provided herein include: (a) about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound VI, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound VII, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound VIII, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound IX, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound X, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier.

[0198] In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.1 mg to about 50 mg (e.g., about 0.1 mg, about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.1 mg to about 50 mg (e.g., about 0.1 mg, about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound III, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.1 mg to about 50 mg (e.g., about 0.1 mg, about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound III-d, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier.In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.1 mg to about 50 mg (e.g., about 0.1 mg, about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound IV, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.1 mg to about 50 mg (e.g., about 0.1 mg, about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound V, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.1 mg to about 50 mg (e.g., about 0.1 mg, about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound VI, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier.In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.1 mg to about 50 mg (e.g., about 0.1 mg, about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound VII, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.1 mg to about 50 mg (e.g., about 0.1 mg, about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound VIII, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.1 mg to about 50 mg (e.g., about 0.1 mg, about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound IX, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier.In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.1 mg to about 50 mg (e.g., about 0.1 mg, about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound X, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier.

[0199] In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.25 mg to about 50 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.25 mg to about 50 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound III, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.25 mg to about 50 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound III-d, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier.In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.25 mg to about 50 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound IV, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.25 mg to about 50 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound V, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.25 mg to about 50 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound VI, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier.In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.25 mg to about 50 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound VII, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.25 mg to about 50 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound VIII, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.25 mg to about 50 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound IX, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier.In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.25 mg to about 50 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound X, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier.

[0200] In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.25 mg to about 25 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, or about 25 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.25 mg to about 25 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, or about 25 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound III, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.25 mg to about 25 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, or about 25 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound III-d, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.25 mg to about 25 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, or about 25 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound IV, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.25 mg to about 25 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, or about 25 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound V, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier.In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.25 mg to about 25 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, or about 25 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound VI, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.25 mg to about 25 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, or about 25 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound VII, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.25 mg to about 25 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, or about 25 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound VIII, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.25 mg to about 25 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, or about 25 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound IX, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.25 mg to about 25 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, or about 25 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound X, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier.

[0201] In some embodiments, the pharmaceutical compositions provided herein include: (a) about 1 mg to about 15 mg (e.g., about 1 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 1 mg to about 15 mg (e.g., about 1 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; (b) Compound III, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 1 mg to about 15 mg (e.g., about 1 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; (b) Compound III-d, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 1 mg to about 15 mg (e.g., about 1 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; (b) Compound IV, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 1 mg to about 15 mg (e.g., about 1 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; (b) Compound V, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 1 mg to about 15 mg (e.g., about 1 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; (b) Compound VI, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; and (c) at least one pharmaceutically acceptable carrier.In some embodiments, the pharmaceutical compositions provided herein include: (a) about 1 mg to about 15 mg (e.g., about 1 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; (b) Compound VII, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 1 mg to about 15 mg (e.g., about 1 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; (b) Compound VIII, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 1 mg to about 15 mg (e.g., about 1 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; (b) Compound IX, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 1 mg to about 15 mg (e.g., about 1 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; (b) Compound X, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; and (c) at least one pharmaceutically acceptable carrier.

[0202] In some embodiments, the pharmaceutical compositions provided herein include: (a) about 1.5 mg to about 14 mg (e.g., about 1.5 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 14 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 1.5 mg to about 14 mg (e.g., about 1.5 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 14 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; (b) Compound III, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 1.5 mg to about 14 mg (e.g., about 1.5 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 14 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; (b) Compound III-d, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 1.5 mg to about 14 mg (e.g., about 1.5 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 14 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; (b) Compound IV, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 1.5 mg to about 14 mg (e.g., about 1.5 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 14 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound V, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier.In some embodiments, the pharmaceutical compositions provided herein include: (a) about 1.5 mg to about 14 mg (e.g., about 1.5 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 14 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; (b) Compound VI, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 1.5 mg to about 14 mg (e.g., about 1.5 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 14 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; (b) Compound VII, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 1.5 mg to about 14 mg (e.g., about 1.5 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 14 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; (b) Compound VIII, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 1.5 mg to about 14 mg (e.g., about 1.5 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 14 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; (b) Compound IX, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 1.5 mg to about 14 mg (e.g., about 1.5 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 14 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound X, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier.

[0203] In some embodiments, the pharmaceutical compositions provided herein include: (a) about 4 mg to about 13 mg (e.g., about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 4 mg to about 13 mg (e.g., about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound III, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 4 mg to about 13 mg (e.g., about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; (b) Compound III-d, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 4 mg to about 13 mg (e.g., about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound IV, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier.In some embodiments, the pharmaceutical compositions provided herein include: (a) about 4 mg to about 13 mg (e.g., about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound V, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 4 mg to about 13 mg (e.g., about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound VI, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 4 mg to about 13 mg (e.g., about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound VII, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 4 mg to about 13 mg (e.g., about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound VIII, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier.In some embodiments, the pharmaceutical compositions provided herein include: (a) about 4 mg to about 13 mg (e.g., about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound IX, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 4 mg to about 13 mg (e.g., about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound X, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier.

[0204] In some embodiments, the pharmaceutical compositions provided herein include: (a) about 8 mg to about 13 mg (e.g., about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 8 mg to about 13 mg (e.g., about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound III, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 8 mg to about 13 mg (e.g., about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound III-d, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 8 mg to about 13 mg (e.g., about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound IV, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 8 mg to about 13 mg (e.g., about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound V, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier.In some embodiments, the pharmaceutical compositions provided herein include: (a) about 8 mg to about 13 mg (e.g., about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound VI, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 8 mg to about 13 mg (e.g., about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound VII, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 8 mg to about 13 mg (e.g., about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound VIII, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 8 mg to about 13 mg (e.g., about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound IX, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 8 mg to about 13 mg (e.g., about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound X, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (c) at least one pharmaceutically acceptable carrier.

[0205] In some embodiments, the pharmaceutical compositions provided herein include: (a) about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (c) Compound V, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (d) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (c) Compound VI, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (d) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (c) Compound VII, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (d) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 5 mg to about 100 mg (e.g., about 7 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 40 mg, about 30 mg to about 60 mg, or about 50 mg to about 80 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (c) Compound VIII, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (d) at least one pharmaceutically acceptable carrier.

[0206] In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.1 mg to about 50 mg (e.g., about 0.1 mg, about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (c) Compound V, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (d) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.1 mg to about 50 mg (e.g., about 0.1 mg, about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (c) Compound VI, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (d) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.1 mg to about 50 mg (e.g., about 0.1 mg, about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (c) Compound VII, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (d) at least one pharmaceutically acceptable carrier.In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.1 mg to about 50 mg (e.g., about 0.1 mg, about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (c) Compound VIII, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (d) at least one pharmaceutically acceptable carrier.

[0207] In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.25 mg to about 50 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (c) Compound V, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (d) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.25 mg to about 50 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (c) Compound VI, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (d) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.25 mg to about 50 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (c) Compound VII, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (d) at least one pharmaceutically acceptable carrier.In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.25 mg to about 50 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg, or about 50 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (c) Compound VIII, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (d) at least one pharmaceutically acceptable carrier.

[0208] In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.25 mg to about 25 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, or about 25 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (c) Compound V, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (d) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.25 mg to about 25 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, or about 25 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (c) Compound VI, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (d) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.25 mg to about 25 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, or about 25 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (c) Compound VII, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (d) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 0.25 mg to about 25 mg (e.g., about 0.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, or about 25 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (c) Compound VIII, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (d) at least one pharmaceutically acceptable carrier.

[0209] In some embodiments, the pharmaceutical compositions provided herein include: (a) about 1 mg to about 15 mg (e.g., about 1 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (c) Compound V, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (d) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 1 mg to about 15 mg (e.g., about 1 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (c) Compound VI, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (d) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 1 mg to about 15 mg (e.g., about 1 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (c) Compound VII, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (d) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 1 mg to about 15 mg (e.g., about 1 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 15 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (c) Compound VIII, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (d) at least one pharmaceutically acceptable carrier.

[0210] In some embodiments, the pharmaceutical compositions provided herein include: (a) about 1.5 mg to about 14 mg (e.g., about 1.5 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 14 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (c) Compound V, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (d) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 1.5 mg to about 14 mg (e.g., about 1.5 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 14 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (c) Compound VI, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (d) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 1.5 mg to about 14 mg (e.g., about 1.5 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 14 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (c) Compound VII, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (d) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 1.5 mg to about 14 mg (e.g., about 1.5 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, about 14 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (c) Compound VIII, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (d) at least one pharmaceutically acceptable carrier.

[0211] In some embodiments, the pharmaceutical compositions provided herein include: (a) about 4 mg to about 13 mg (e.g., about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (c) Compound V, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (d) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 4 mg to about 13 mg (e.g., about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (c) Compound VI, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (d) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 4 mg to about 13 mg (e.g., about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (c) Compound VII, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (d) at least one pharmaceutically acceptable carrier.In some embodiments, the pharmaceutical compositions provided herein include: (a) about 4 mg to about 13 mg (e.g., about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (c) Compound VIII, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (d) at least one pharmaceutically acceptable carrier.

[0212] In some embodiments, the pharmaceutical compositions provided herein include: (a) about 8 mg to about 13 mg (e.g., about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (c) Compound V, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (d) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 8 mg to about 13 mg (e.g., about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (c) Compound VI, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (d) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 8 mg to about 13 mg (e.g., about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (c) Compound VII, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (d) at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions provided herein include: (a) about 8 mg to about 13 mg (e.g., about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, or about 13 mg) of Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (b) Compound II, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; (c) Compound VIII, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (d) at least one pharmaceutically acceptable carrier.

[0213] Any pharmaceutical composition disclosed herein may include at least one pharmaceutically acceptable carrier. In some embodiments, at least one pharmaceutically acceptable carrier is selected from a pharmaceutically acceptable vehicle and a pharmaceutically acceptable adjuvant. In some embodiments, at least one pharmaceutically acceptable is selected from a pharmaceutically acceptable filler, a disintegrant, a surfactant, a binder, and a lubricant.

[0214] The pharmaceutical compositions described herein are useful for treating cystic fibrosis and other CFTR-mediated diseases.

[0215] As described above, the pharmaceutical composition disclosed herein may optionally further include at least one pharmaceutically acceptable carrier. At least one pharmaceutically acceptable carrier may be selected from adjuvants and vehicles. As used herein, at least one pharmaceutically acceptable carrier comprises any and all solvents, diluents, other liquid vehicles, dispersing aids, suspension aids, surfactants, isotonic agents, thickeners, emulsifiers, preservatives, solid binders and lubricants suitable for the desired specific dosage form. Various carriers for formulating pharmaceutical compositions and known techniques for preparing the same are disclosed in Remington: The Science and Practice of Pharmacy, 21st edition, 2005, edited by DB Troy, Lippincott Williams & Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, edited by J. Swarbrick and JC Boylan, 1988-1999, Marcel Dekker, New York. Unless any conventional carrier is incompatible with the compounds of the present disclosure, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component of the pharmaceutical composition, its use is contemplated to be within the scope of the present disclosure. Non-limiting examples of suitable pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins (such as human serum albumin), buffer substances (such as phosphates, glycine, sorbic acid and potassium sorbate), partial glyceride mixtures of saturated vegetable fatty acids, water, salts and electrolytes (such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride and zinc salts), colloidal silicon dioxide, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene block polymers, lanolin, sugars (such as lactose, glucose and sucrose ), starches (such as corn starch and potato starch), cellulose and its derivatives (such as sodium carboxymethylcellulose, ethylcellulose and cellulose acetate), powdered tragacanth, malt, gelatin, talc, excipients (such as cocoa butter and suppository waxes), oils (such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil), glycols (such as propylene glycol and polyethylene glycol), esters (such as ethyl oleate and ethyl laurate), agar, buffers (such as magnesium hydroxide and aluminum hydroxide), alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethanol, phosphate buffer, non-toxic compatible lubricants (such as sodium laurate sulfate and magnesium stearate), coloring agents, release agents, encapsulating agents, sweeteners, flavoring agents, fragrances, preservatives and antioxidants.

[0216] Non-limiting exemplary embodiments

[0217] 1. A method for treating cystic fibrosis, the method comprising administering to a patient in need thereof from about 5 mg to about 100 mg of Compound I per day:

[0218]

[0219] Or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0220] 2. The method according to embodiment 1, wherein the method comprises administering about 7 mg to about 90 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

[0221] 3. The method according to embodiment 1 or embodiment 2, wherein the method comprises administering about 10 mg to about 80 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

[0222] 4. The method of any one of embodiments 1 to 3, wherein the method comprises administering from about 10 mg to about 40 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

[0223] 5. The method of any one of embodiments 1 to 3, wherein the method comprises administering about 30 mg to about 60 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

[0224] 6. The method of any one of embodiments 1 to 3, wherein the method comprises administering about 50 mg to about 80 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

[0225] 7. The method of any one of embodiments 1 to 3, wherein about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg or about 80 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof is administered daily.

[0226] 8. The method of any one of embodiments 1 to 3, wherein about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg or about 80 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof is administered daily.

[0227] 9. A method for treating cystic fibrosis, the method comprising administering to a patient in need thereof about 0.1 mg to about 50 mg per day of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0228] 10. The method of embodiment 9, wherein the method comprises administering from about 0.25 mg to about 50 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

[0229] 11. The method of embodiment 9 or embodiment 10, wherein the method comprises administering about 0.25 mg to about 25 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

[0230] 12. The method of any one of embodiments 9 to 11, wherein the method comprises administering from about 1 mg to about 15 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

[0231] 13. The method of any one of embodiments 9 to 12, wherein the method comprises administering from about 1.5 mg to about 14 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

[0232] 14. The method of any one of embodiments 9 to 13, wherein the method comprises administering from about 4 mg to about 13 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

[0233] 15. The method of any one of embodiments 9 to 14, wherein the method comprises administering from about 8 mg to about 13 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

[0234] 16. The method of embodiment 9, wherein about 0.1 mg, about 0.25 mg, about 1 mg, about 1.5 mg, about 2.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, about 13 mg, about 14 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg or about 50 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0235] 17. A method of treating cystic fibrosis, the method comprising administering to a patient in need thereof from about 5 mg to about 100 mg per day of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof, and wherein the patient is heterozygous and has one F508del mutation.

[0236] 18. The method of embodiment 17, wherein the method comprises administering from about 7 mg to about 90 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day, and wherein the patient is heterozygous and has one F508del mutation.

[0237] 19. The method of embodiment 17 or embodiment 18, wherein the method comprises administering from about 10 mg to about 80 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day, and wherein the patient is heterozygous and has one F508del mutation.

[0238] 20. The method of any one of embodiments 17 to 19, wherein the method comprises administering from about 10 mg to about 40 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day, and wherein the patient is heterozygous and has one F508del mutation.

[0239] 21. The method of any one of embodiments 17 to 19, wherein the method comprises administering from about 30 mg to about 60 mg per day of Compound I, or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof, and wherein the patient is heterozygous and has one F508del mutation.

[0240] 22. The method of any one of embodiments 17 to 19, wherein the method comprises administering from about 50 mg to about 80 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day, and wherein the patient is heterozygous and has one F508del mutation.

[0241] 23. The method of any one of embodiments 17 to 19, wherein about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, or about 80 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof is administered daily, and wherein the patient is heterozygous and has one F508del mutation.

[0242] 24. The method of any one of embodiments 17 to 19, wherein about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, or about 80 mg of Compound I, or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof, is administered daily, and wherein the patient is heterozygous and has one F508del mutation.

[0243] 25. A method of treating cystic fibrosis, the method comprising administering to a patient in need thereof from about 0.1 mg to about 50 mg per day of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof, and wherein the patient is heterozygous and has one F508del mutation.

[0244] 26. The method of embodiment 25, wherein the method comprises administering from about 0.25 mg to about 50 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day, and wherein the patient is heterozygous and has one F508del mutation.

[0245] 27. The method of embodiment 25 or embodiment 26, wherein the method comprises administering from about 0.25 mg to about 25 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day, and wherein the patient is heterozygous and has one F508del mutation.

[0246] 28. The method of any one of embodiments 25 to 27, wherein the method comprises administering from about 1 mg to about 15 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day, and wherein the patient is heterozygous and has one F508del mutation.

[0247] 29. The method of any one of embodiments 25 to 28, wherein the method comprises administering from about 1.5 mg to about 14 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day, and wherein the patient is heterozygous and has one F508del mutation.

[0248] 30. The method of any one of embodiments 25 to 29, wherein the method comprises administering from about 4 mg to about 13 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day, and wherein the patient is heterozygous and has one F508del mutation.

[0249] 31. The method of any one of embodiments 25 to 30, wherein the method comprises administering from about 8 mg to about 13 mg per day of Compound I, or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof, and wherein the patient is heterozygous and has one F508del mutation.

[0250] 32. The method of embodiment 25, wherein about 0.1 mg, about 0.25 mg, about 1 mg, about 1.5 mg, about 2.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, about 13 mg, about 13.5 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 21 mg, about 22 mg, about 23 mg, about 24 mg, about 25 mg, about 26 mg, about 27 mg, about 28 mg, about 29 mg, about 30 mg, about 31 mg, about 32 about 13 mg, about 14 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg or about 50 mg of Compound 1 or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof, and wherein the patient is heterozygous and has one F508del mutation.

[0251] 33. The method of any one of embodiments 1 to 33, wherein Compound 1 or a deuterated derivative or pharmaceutically acceptable salt thereof is administered in a single dose once a day.

[0252] 34. The method of any one of embodiments 1 to 33, wherein Compound 1 or a deuterated derivative or pharmaceutically acceptable salt thereof is administered in two doses per day.

[0253] 35. The method of any one of embodiments 1 to 34, further comprising administering one or more additional therapeutic agents.

[0254] 36. The method of embodiment 35, wherein the one or more additional therapeutic agents comprises a compound having CFTR modulating activity or a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0255] 37. The method of Embodiment 35 or Embodiment 36, wherein the one or more additional therapeutic agents comprises a CFTR corrector.

[0256] 38. The method of any one of embodiments 35 to 37, wherein the one or more additional therapeutic agents comprises a compound selected from:

[0257] (a) (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylprop-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound II):

[0258]

[0259] (b) 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound IV):

[0260]

[0261] (c) N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound V):

[0262]

[0263] (d) N-(Benzenesulfonyl)-6-[3-[2-[1-(trifluoromethyl)cyclopropyl]ethoxy]pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound VI):

[0264]

[0265] (e) (14S)-8-[3-(2-{dispiro[2.0.2.1]hept-7-yl}ethoxy)-1H-pyrazol-1-yl]-12,12-dimethyl-2λ 6 -Thia-3,9,11,18,23-pentazatetracyclo[17.3.1.111,14.05,10]tetracosyl-1(22),5,7,9,19(23),20-hexaene-2,2,4-trione (Compound VII):

[0266]

[0267] (f) (11R)-6-(2,6-dimethylphenyl)-11-(2-methylpropyl)-12-{spiro[2.3]hexan-5-yl}-9-oxa-2λ 6-Thia-3,5,12,19-tetraazatricyclo[12.3.1.14,8]nonadecan-1(17),4(19),5,7,14(18),15-hexaene-2,2,13-trione (Compound VIII):

[0268]

[0269] (g) N-(Benzenesulfonyl)-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound IX):

[0270]

[0271] (h) N-[(6-amino-2-pyridinyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound X): and deuterated derivatives and pharmaceutically acceptable salts thereof.

[0272] 39. The method of any one of embodiments 35 to 38, wherein the one or more additional therapeutic agents comprises at least one compound selected from the group consisting of PTI-428, ABBV-2222, ABBV-2851, GLPG2737, ABBV-3221, ABBV-3748, ABBV-3903, ABBV-119, ABBV-2851, FDL-169, ARN5562, ARN21586, ARN22081, ARN22652, ARN23765, ARN23766, and PTI-801.

[0273] 40. The method of any one of embodiments 35 to 39, wherein the one or more additional therapeutic agents comprises a CFTR potentiator enhancer.

[0274] 41. The method of any one of embodiments 35 to 40, wherein the one or more additional therapeutic agents comprises ASP-11.

[0275] 42. The method of any one of embodiments 35 to 41, wherein the one or more additional therapeutic agents comprises a CFTR potentiator.

[0276] 43. The method of any one of embodiments 35 to 42, wherein the one or more additional therapeutic agents comprises a compound selected from:

[0277] (a) N-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (Compound III):

[0278]

[0279] (b) N-(2-(tert-butyl)-5-hydroxy-4-(2-(methyl-d3)propan-2-yl-1,1,1,3,3,3-d6)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (Compound III-d):

[0280] and deuterated derivatives and pharmaceutically acceptable salts thereof.

[0281] 44. The method of any one of embodiments 35 to 43, wherein the one or more additional therapeutic agents comprises at least one compound selected from the group consisting of FDL-176, PTI-808, GLPG1837 / ABBV-974, GLPG2451 / ABBV-2451, QBW251 (Isencattor), GLPG3067 / ABBV-3067 (Navocattor), and ABBV-191.

[0282] 45. The method of any one of embodiments 35 to 44, wherein the one or more additional therapeutic agents comprises a CFTR amplifying agent.

[0283] 46. ​​The method of any one of embodiments 35 to 45, wherein the one or more additional therapeutic agents comprises PTI-428.

[0284] 47. The method of any one of embodiments 35 to 46, wherein the one or more additional therapeutic agents comprises a CFTR read-through agent.

[0285] 48. The method of any one of embodiments 35 to 46, wherein the one or more additional therapeutic agents comprises ELX-02.

[0286] 49. The method of any one of embodiments 35 to 48, wherein the one or more additional therapeutic agents comprises a nucleic acid therapy.

[0287] 50. The method of any one of embodiments 35 to 49, wherein the one or more additional therapeutic agents comprises at least one agent selected from the group consisting of: MRT5005, Lunar-CF, and RCT223.

[0288] 51. The method of any one of embodiments 35 to 50, wherein said one or more additional therapeutic agents comprises an ENaC inhibitor.

[0289] 52. The method of any one of embodiments 35 to 51, wherein the one or more additional therapeutic agents comprises amiloride, ETD001, CF552, GS-9411, GS-5737, P-1037 (VX-371), P-1055 (VX-551), AZD5634, SPX-101, Ionis-ENaC-2.5Rx, BI 1265162, or ARO-ENaC1001.

[0290] 53. The method of any one of embodiments 35 to 52, wherein said one or more additional therapeutic agents comprises a TMEM16A modulator.

[0291] 54. The method of any one of embodiments 35 to 53, wherein the one or more additional therapeutic agents comprises ETD002.

[0292] 55. The method of any one of embodiments 35 to 54, wherein the one or more additional therapeutic agents comprises a GPR39 agonist.

[0293] 56. The method of any one of embodiments 35 to 55, wherein the one or more additional therapeutic agents comprises DS-1039.

[0294] 57. A pharmaceutical composition comprising about 5 mg to about 100 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0295] 58. The pharmaceutical composition of embodiment 57, wherein the composition comprises about 7 mg to about 90 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0296] 59. The pharmaceutical composition of Embodiment 57 or Embodiment 58, wherein the composition comprises about 10 mg to about 80 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0297] 60. The pharmaceutical composition of any one of embodiments 57 to 59, wherein the composition comprises about 10 mg to about 40 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0298] 61. The pharmaceutical composition of any one of embodiments 57 to 59, wherein the composition comprises about 30 mg to about 60 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0299] 62. The pharmaceutical composition of any one of embodiments 57 to 59, wherein the composition comprises about 50 mg to about 80 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0300] 63. The pharmaceutical composition of any one of embodiments 57 to 59, wherein the composition comprises about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg or about 80 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0301] 64. The pharmaceutical composition of any one of embodiments 57 to 59, wherein the composition comprises about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg or about 80 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0302] 65. A pharmaceutical composition comprising about 0.1 mg to about 50 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0303] 66. The pharmaceutical composition of embodiment 65, wherein the composition comprises about 0.25 mg to about 50 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0304] 67. The pharmaceutical composition of Embodiment 65 or Embodiment 66, wherein the composition comprises about 0.25 mg to about 25 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0305] 68. The pharmaceutical composition of any one of embodiments 65 to 67, wherein the composition comprises about 1 mg to about 15 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0306] 69. The pharmaceutical composition of any one of embodiments 65 to 68, wherein the composition comprises about 1.5 mg to about 14 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0307] 70. The pharmaceutical composition of any one of embodiments 65 to 69, wherein the composition comprises about 4 mg to about 13 mg of Compound 1 or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0308] 71. The pharmaceutical composition of any one of embodiments 65 to 70, wherein the composition comprises about 8 mg to about 13 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0309] 72. The pharmaceutical composition of embodiment 65, wherein the composition comprises about 0.1 mg, about 0.25 mg, about 1 mg, about 1.5 mg, about 2.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 About 150 mg, about 160 mg, about 180 mg, about 250 mg, about 260 mg, about 280 mg, about 290 mg, about 300 mg, about 320 mg, about 350 mg, about 370 mg, about 370 mg, about 400 mg, about 420 mg, about 450 mg, about 470 mg, or about 500 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0310] 73. The pharmaceutical composition of any one of embodiments 57 to 72, wherein the composition further comprises one or more additional therapeutic agents.

[0311] 74. A pharmaceutical composition according to embodiment 73, wherein the one or more additional therapeutic agents include a compound having CFTR modulating activity or a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0312] 75. The pharmaceutical composition of Embodiment 73 or Embodiment 74, wherein the one or more additional therapeutic agents comprises a CFTR corrector.

[0313] 76. The pharmaceutical composition of any one of embodiments 73 to 75, wherein the one or more additional therapeutic agents comprises a compound selected from:

[0314] (a) Compound II;

[0315] (b) Compound IV;

[0316] (c) Compound V;

[0317] (d) Compound VI;

[0318] (e) Compound VII;

[0319] (f) Compound VIII;

[0320] (g) Compound IX; and

[0321] (i) Compound X; and deuterated derivatives and pharmaceutically acceptable salts thereof.

[0322] 77. The pharmaceutical composition of any one of embodiments 73 to 76, wherein the one or more additional therapeutic agents comprises at least one compound selected from the group consisting of PTI-428, ABBV-2222, ABBV-2851, GLPG2737, ABBV-3221, ABBV-3748, ABBV-3903, ABBV-119, ABBV-2851, FDL-169, ARN5562, ARN21586, ARN22081, ARN22652, ARN23765, ARN23766, and PTI-801.

[0323] 78. The pharmaceutical composition of any one of embodiments 73 to 77, wherein the one or more additional therapeutic agents comprises a CFTR potentiator enhancer.

[0324] 79. The pharmaceutical composition of any one of embodiments 73 to 78, wherein the one or more additional therapeutic agents comprises ASP-11.

[0325] 80. The pharmaceutical composition of any one of embodiments 73 to 79, wherein the one or more additional therapeutic agents comprises a CFTR potentiator.

[0326] 81. The pharmaceutical composition of any one of embodiments 73 to 80, wherein the one or more additional therapeutic agents comprises a compound selected from the group consisting of Compound III; Compound III-d; and deuterated derivatives and pharmaceutically acceptable salts thereof.

[0327] 82. The pharmaceutical composition of any one of embodiments 73 to 81, wherein the one or more additional therapeutic agents comprises at least one compound selected from the group consisting of FDL-176, PTI-808, GLPG1837 / ABBV-974, GLPG2451 / ABBV-2451, QBW251 (Isencattor), GLPG3067 / ABBV-3067 (Navocattor), and ABBV-191.

[0328] 83. The pharmaceutical composition of any one of embodiments 73 to 82, wherein the one or more additional therapeutic agents comprises a CFTR amplifier.

[0329] 84. The pharmaceutical composition of any one of embodiments 73 to 83, wherein the one or more additional therapeutic agents comprises PTI-428.

[0330] 85. The pharmaceutical composition of any one of embodiments 73 to 84, wherein the one or more additional therapeutic agents comprises a CFTR read-through agent.

[0331] 86. The pharmaceutical composition of any one of embodiments 73 to 85, wherein the one or more additional therapeutic agents comprises ELX-02.

[0332] 87. The pharmaceutical composition of any one of embodiments 73 to 86, wherein the one or more additional therapeutic agents comprises a nucleic acid therapy.

[0333] 88. The pharmaceutical composition of any one of embodiments 73 to 87, wherein the one or more additional therapeutic agents comprises at least one agent selected from the group consisting of: MRT5005, Lunar-CF, and RCT223.

[0334] 89. The pharmaceutical composition of any one of embodiments 73 to 88, wherein the one or more additional therapeutic agents comprises an ENaC inhibitor.

[0335] 90. The pharmaceutical composition of any one of embodiments 73 to 89, wherein the one or more additional therapeutic agents comprises amiloride, ETD001, CF552, GS-9411, GS-5737, P-1037 (VX-371), P-1055 (VX-551), AZD5634, SPX-101, Ionis-ENaC-2.5Rx, BI 1265162, or ARO-EnaC1001.

[0336] 91. The pharmaceutical composition of any one of embodiments 73 to 90, wherein the one or more additional therapeutic agents comprises a TMEM16A modulator.

[0337] 92. The pharmaceutical composition of any one of embodiments 73 to 91, wherein the one or more additional therapeutic agents comprises ETD002.

[0338] 93. The pharmaceutical composition of any one of embodiments 73 to 92, wherein the one or more additional therapeutic agents comprises a GPR39 agonist.

[0339] 94. The pharmaceutical composition of any one of embodiments 73 to 93, wherein the one or more additional therapeutic agents comprises DS-1039.

[0340] 95. Compound I or a deuterated derivative or a pharmaceutically acceptable salt or a pharmaceutical composition according to any one of Embodiments 57 to 94, for use in a method of treating cystic fibrosis in a patient, the method comprising administering about 5 mg to about 100 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

[0341] 96. A compound, deuterated derivative, salt or composition for use according to embodiment 95, wherein the method comprises administering from about 7 mg to about 90 mg of Compound 1 or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

[0342] 97. A compound, deuterated derivative, salt or composition for use according to Embodiment 95 or Embodiment 96, wherein the method comprises administering from about 10 mg to about 80 mg of Compound I or an equivalent amount of a deuterated derivative or pharmaceutically acceptable salt thereof per day.

[0343] 98. The compound, deuterated derivative, salt or composition for use according to any one of embodiments 95 to 97, wherein the method comprises administering from about 10 mg to about 40 mg of Compound 1 or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

[0344] 99. The compound, deuterated derivative, salt or composition for use according to any one of embodiments 95 to 97, wherein the method comprises administering about 30 mg to about 60 mg of Compound 1 or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

[0345] 100. The compound, deuterated derivative, salt or composition for use according to any one of embodiments 95 to 97, wherein the method comprises administering about 50 mg to about 80 mg of Compound 1 or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

[0346] 101. The compound, deuterated derivative, salt or composition for use according to any one of Embodiments 95 to 97, wherein the method comprises administering about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg or about 80 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

[0347] 102. The compound, deuterated derivative, salt or composition for use according to any one of Embodiments 95 to 97, wherein the method comprises administering about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg or about 80 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

[0348] 103. Compound I or a deuterated derivative or a pharmaceutically acceptable salt thereof or a pharmaceutical composition according to any one of Embodiments 57 to 94, for use in a method of treating cystic fibrosis in a patient, the method comprising administering about 0.1 mg to about 50 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

[0349] 104. The compound, deuterated derivative, salt or composition for use according to embodiment 103, wherein the method comprises administering from about 0.25 mg to about 50 mg of Compound 1 or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

[0350] 105. The compound, deuterated derivative, salt or composition for use according to Embodiment 103 or Embodiment 104, wherein the method comprises administering from about 0.25 mg to about 25 mg of Compound 1 or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

[0351] 106. The compound, deuterated derivative, salt or composition for use according to any one of embodiments 103 to 105, wherein the method comprises administering from about 1 mg to about 15 mg of Compound 1 or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

[0352] 107. The compound, deuterated derivative, salt or composition for use according to any one of embodiments 103 to 106, wherein the method comprises administering about 1.5 mg to about 14 mg of Compound 1 or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

[0353] 108. The compound, deuterated derivative, salt or composition for use according to any one of embodiments 103 to 107, wherein the method comprises administering about 4 mg to about 13 mg of Compound 1 or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

[0354] 109. The compound, deuterated derivative, salt or composition for use according to any one of embodiments 103 to 108, wherein the method comprises administering from about 8 mg to about 13 mg of Compound 1 or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

[0355] 110. The compound, deuterated derivative, salt, or composition for use according to embodiment 103, wherein the method comprises administering about 0.1 mg, about 0.25 mg, about 1 mg, about 1.5 mg, about 2.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11.5 mg, about 12.5 mg, about 13.5 mg, about 14.5 mg, about 15.5 mg, about 16.5 mg, about 17.5 mg, about 18.5 mg, about 19.5 mg, about 20.5 mg, about 21.5 mg, about 22.5 mg, about 23.5 mg, about 24.5 mg, about 25.5 mg, about 26.5 mg, about 27.5 mg, about 28.5 mg, about 29.5 mg, about 30.5 mg, about 31.5 mg, about 32.5 mg, about 33.5 mg, about 34.5 mg, about 35.5 mg, about 36.5 mg, about 37.5 mg, about 38.5 mg, about 39.5 mg, about 40.5 mg, about 41.5 mg, about 42.5 mg, about 43.5 mg, about 44.5 mg, about 45.5 mg, about 46.5 mg, about 47.5 mg, about 48.5 mg, about 49.5 mg, about 50.5 mg, about 51.5 mg, about 52.5 mg, about 53.5 mg, about 5 1 mg, about 11.5 mg, about 12 mg, about 12.5 mg, about 13 mg, about 14 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg or about 50 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0356] 111. Compound I or a deuterated derivative or a pharmaceutically acceptable salt thereof or a pharmaceutical composition according to any one of embodiments 57 to 94, for use in a method of treating cystic fibrosis in a patient, the method comprising administering about 5 mg to about 100 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day, and wherein the patient is heterozygous and has one F508del mutation.

[0357] 112. A compound, deuterated derivative, salt or composition for use according to embodiment 111, wherein the method comprises administering from about 7 mg to about 90 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day, and wherein the patient is heterozygous and has one F508del mutation.

[0358] 113. A compound, deuterated derivative, salt or composition for use according to Embodiment 111 or Embodiment 112, wherein the method comprises administering about 10 mg to about 80 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day, and wherein the patient is heterozygous and has one F508del mutation.

[0359] 114. The compound, deuterated derivative, salt or composition for use according to any one of embodiments 111 to 113, wherein the method comprises administering about 10 mg to about 40 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day, and wherein the patient is heterozygous and has one F508del mutation.

[0360] 115. The compound, deuterated derivative, salt or composition for use according to any one of embodiments 111 to 113, wherein the method comprises administering about 30 mg to about 60 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day, and wherein the patient is heterozygous and has one F508del mutation.

[0361] 116. The compound, deuterated derivative, salt or composition for use according to any one of embodiments 111 to 113, wherein the method comprises administering about 50 mg to about 80 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day, and wherein the patient is heterozygous and has one F508del mutation.

[0362] 117. A compound, deuterated derivative, salt or composition for use according to any one of embodiments 111 to 113, wherein the method comprises administering about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg or about 80 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day, and wherein the patient is heterozygous and has one F508del mutation.

[0363] 118. The compound, deuterated derivative, salt or composition for use of any one of embodiments 111 to 113, wherein the method comprises administering about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg or about 80 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof, and wherein the patient is heterozygous and has one F508del mutation.

[0364] 119. Compound I or a deuterated derivative or a pharmaceutically acceptable salt or a pharmaceutical composition according to any one of embodiments 57 to 94, for use in a method of treating cystic fibrosis in a patient, the method comprising administering about 0.1 mg to about 50 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day, and wherein the patient is heterozygous and has one F508del mutation.

[0365] 120. A compound, deuterated derivative, salt or composition for use according to embodiment 119, wherein the method comprises administering from about 0.25 mg to about 50 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day, and wherein the patient is heterozygous and has one F508del mutation.

[0366] 121. A compound, deuterated derivative, salt or composition for use according to Embodiment 119 or Embodiment 120, wherein the method comprises administering from about 0.25 mg to about 25 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day, and wherein the patient is heterozygous and has one F508del mutation.

[0367] 122. The compound, deuterated derivative, salt or composition for use according to any one of embodiments 119 to 121, wherein the method comprises administering from about 1 mg to about 15 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day, and wherein the patient is heterozygous and has one F508del mutation.

[0368] 123. The compound, deuterated derivative, salt or composition for use according to any one of embodiments 119 to 122, wherein the method comprises administering from about 1.5 mg to about 14 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day, and wherein the patient is heterozygous and has one F508del mutation.

[0369] 124. The compound, deuterated derivative, salt or composition for use according to any one of embodiments 119 to 123, wherein the method comprises administering from about 4 mg to about 13 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day, and wherein the patient is heterozygous and has one F508del mutation.

[0370] 125. The compound, deuterated derivative, salt or composition for use according to any one of embodiments 119 to 124, wherein the method comprises administering about 8 mg to about 13 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day, and wherein the patient is heterozygous and has one F508del mutation.

[0371] 126. The compound, deuterated derivative, salt, or composition for use according to embodiment 119, wherein the method comprises administering about 0.1 mg, about 0.25 mg, about 1 mg, about 1.5 mg, about 2.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12.5 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 21 mg, about 22 mg, about 23 mg, about 24 mg, about 25 mg, about 26 mg, about 27 mg, about 28 mg, about 29 mg, about 30 mg, about 31 mg, about 32 mg, about 33 mg, about 34 mg, about 35 mg, about 36 mg, about 37 mg, about 38 mg, about 39 mg, about 40 mg, about 41 mg, about 42 mg, about 43 mg, about 44 mg, about 45 mg, about 46 mg, about 47 mg, about 48 mg, about 49 mg, 2 mg, about 12.5 mg, about 13 mg, about 14 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg or about 50 mg of Compound 1 or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof, and wherein the patient is heterozygous and has one F508del mutation.

[0372] 127. The compound, deuterated derivative, salt or composition for use according to any one of Embodiments 95 to 127, wherein the method comprises administering Compound 1 or a deuterated derivative or pharmaceutically acceptable salt thereof in a single dose once a day.

[0373] 128. The compound, deuterated derivative, salt or composition for use according to any one of Embodiments 95 to 127, wherein the method comprises administering Compound 1 or a deuterated derivative or pharmaceutically acceptable salt thereof in two doses per day.

[0374] 129. The compound, deuterated derivative, salt or composition for use of any one of embodiments 95 to 129, wherein the method further comprises administering one or more additional therapeutic agents.

[0375] 130. The compound, deuterated derivative, salt or composition for use according to Embodiment 129, wherein the one or more additional therapeutic agents comprises a compound having CFTR modulating activity or a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0376] 131. The compound, deuterated derivative, salt, or composition for use of Embodiment 129 or Embodiment 130, wherein the one or more additional therapeutic agents comprises a CFTR corrector.

[0377] 132. The compound, deuterated derivative, salt, or composition for use according to any one of embodiments 129 to 131, wherein the one or more additional therapeutic agents comprises a compound selected from:

[0378] (a) Compound II;

[0379] (b) Compound IV;

[0380] (c) Compound V;

[0381] (d) Compound VI;

[0382] (e) Compound VII;

[0383] (f) Compound VIII;

[0384] (g) Compound IX; and

[0385] (h) Compound X; and deuterated derivatives thereof and pharmaceutically acceptable salts of any of the foregoing.

[0386] 133. The compound, deuterated derivative, salt or composition for use according to any one of embodiments 129 to 132, wherein the one or more additional therapeutic agents include at least one compound selected from the group consisting of PTI-428, ABBV-2222, ABBV-2851, GLPG2737, ABBV-3221, ABBV-3748, ABBV-3903, ABBV-119, ABBV-2851, FDL-169, ARN5562, ARN21586, ARN22081, ARN22652, ARN23765, ARN23766 and PTI-801.

[0387] 134. The compound, deuterated derivative, salt or composition for use of any one of embodiments 129 to 133, wherein the one or more additional therapeutic agents comprises a CFTR potentiator enhancer.

[0388] 135. The compound, deuterated derivative, salt or composition for use according to any one of embodiments 129 to 134, wherein the one or more additional therapeutic agents comprises ASP-11.

[0389] 136. The compound, deuterated derivative, salt or composition for use of any one of embodiments 129 to 135, wherein the one or more additional therapeutic agents comprises a CFTR potentiator.

[0390] 137. A compound, deuterated derivative, salt or composition for use according to any one of Embodiments 129 to 136, wherein the one or more additional therapeutic agents comprises a compound selected from the group consisting of Compound III; Compound III-d; and pharmaceutically acceptable salts and deuterated derivatives thereof.

[0391] 138. The compound, deuterated derivative, salt or composition for use according to any one of embodiments 129 to 137, wherein the one or more additional therapeutic agents include at least one compound selected from the group consisting of FDL-176, PTI-808, GLPG1837 / ABBV-974, GLPG2451 / ABBV-2451, QBW251 (Isencato), GLPG3067 / ABBV-3067 (Navocato) and ABBV-191.

[0392] 139. The compound, deuterated derivative, salt or composition for use of any one of embodiments 129 to 138, wherein the one or more additional therapeutic agents comprises a CFTR amplifier.

[0393] 140. The compound, deuterated derivative, salt or composition for use of any one of embodiments 129 to 139, wherein the one or more additional therapeutic agents comprises PTI-428.

[0394] 141. The compound, deuterated derivative, salt or composition for use of any one of embodiments 129 to 140, wherein the one or more additional therapeutic agents comprises a CFTR read-through agent.

[0395] 142. The compound, deuterated derivative, salt or composition for use according to any one of embodiments 129 to 141, wherein the one or more additional therapeutic agents comprises ELX-02.

[0396] 143. The compound, deuterated derivative, salt or composition for use of any one of embodiments 129 to 142, wherein the one or more additional therapeutic agents comprises a nucleic acid therapy.

[0397] 144. The compound, deuterated derivative, salt or composition for use according to any one of embodiments 129 to 143, wherein the one or more additional therapeutic agents comprises at least one agent selected from the group consisting of MRT5005, Lunar-CF and RCT223.

[0398] 145. The compound, deuterated derivative, salt or composition for use of any one of embodiments 129 to 144, wherein the one or more additional therapeutic agents comprises an ENaC inhibitor.

[0399] 146. The compound, deuterated derivative, salt or composition for use of any one of embodiments 129 to 145, wherein the one or more additional therapeutic agents comprises amiloride, ETD001, CF552, GS-9411, GS-5737, P-1037 (VX-371), P-1055 (VX-551), AZD5634, SPX-101, Ionis-ENaC-2.5Rx, BI 1265162 and ARO-ENaC1001.

[0400] 147. The compound, deuterated derivative, salt or composition for use according to any one of embodiments 129 to 146, wherein the one or more additional therapeutic agents comprises a TMEM16A modulator.

[0401] 148. The compound, deuterated derivative, salt or composition for use according to any one of embodiments 129 to 147, wherein the one or more additional therapeutic agents comprises ETD002.

[0402] 149. The compound, deuterated derivative, salt or composition for use according to any one of embodiments 129 to 148, wherein the one or more additional therapeutic agents comprises a GPR39 agonist.

[0403] 150. The compound, deuterated derivative, salt, or composition for use of any one of embodiments 129 to 149, wherein the one or more additional therapeutic agents comprises DS-1039.

[0404] 151. A use of Compound 1 or a deuterated derivative or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to any one of Embodiments 57 to 94, for the preparation of a medicament for the treatment of cystic fibrosis, wherein the medicament comprises about 5 mg to about 100 mg of Compound 1 or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0405] 152. The use according to embodiment 151, wherein the medicament comprises about 7 mg to about 90 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0406] 153. The use according to Embodiment 151 or Embodiment 152, wherein the medicament comprises about 10 mg to about 80 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0407] 154. The use of any one of embodiments 151 to 153, wherein the medicament comprises about 10 mg to about 40 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0408] 155. The use of any one of embodiments 151 to 153, wherein the medicament comprises about 30 mg to about 60 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0409] 156. The use of any one of embodiments 151 to 153, wherein the medicament comprises about 50 mg to about 80 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0410] 157. The use of any one of embodiments 151 to 153, wherein the medicament comprises administering about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg or about 80 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0411] 158. The use of any one of embodiments 151 to 153, wherein the medicament comprises administering about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg or about 80 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

[0412] 159. A use of Compound 1 or a deuterated derivative or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to any one of Embodiments 57 to 94, for the preparation of a medicament for the treatment of cystic fibrosis, wherein the medicament comprises about 0.1 mg to about 50 mg of Compound 1 or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0413] 160. The use according to embodiment 159, wherein the medicament comprises about 0.25 mg to about 50 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0414] 161. The use according to Embodiment 159 or Embodiment 160, wherein the medicament comprises about 0.25 mg to about 25 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0415] 162. The use of any one of embodiments 159 to 161, wherein the medicament comprises about 1 mg to about 15 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0416] 163. The use of any one of embodiments 159 to 162, wherein the medicament comprises about 1.5 mg to about 14 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0417] 164. The use of any one of embodiments 159 to 162, wherein the medicament comprises about 4 mg to about 13 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0418] 165. The use of any one of embodiments 159 to 163, wherein the medicament comprises about 8 mg to about 13 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0419] 166. The use according to embodiment 159, wherein the medicament comprises administering about 0.1 mg, about 0.25 mg, about 1 mg, about 1.5 mg, about 2.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 About 150 mg, about 160 mg, about 180 mg, about 250 mg, about 260 mg, about 280 mg, about 290 mg, about 300 mg, about 320 mg, about 350 mg, about 370 mg, about 370 mg, about 400 mg, about 420 mg, about 450 mg, about 470 mg, or about 500 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0420] 167. The use according to any one of embodiments 151 to 166, wherein the medicament is formulated for administration in a single dose, once a day.

[0421] 168. The use according to any one of embodiments 151 to 166, wherein the medicament is formulated to be administered in two doses per day.

[0422] 169. The use according to any one of embodiments 151 to 168, wherein the medicament is formulated for administration in combination with one or more additional therapeutic agents.

[0423] 170. The use according to embodiment 169, wherein the one or more additional therapeutic agents include a compound having CFTR modulating activity or a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0424] 171. The use of Embodiment 169 or Embodiment 170, wherein the one or more additional therapeutic agents comprises a CFTR corrector.

[0425] 172. The use of any one of embodiments 169 to 171, wherein the one or more additional therapeutic agents comprises a compound selected from:

[0426] (a) Compound II;

[0427] (b) Compound IV;

[0428] (c) Compound V;

[0429] (d) Compound VI;

[0430] (e) Compound VII;

[0431] (f) Compound VIII;

[0432] (g) Compound IX; and

[0433] (h) Compound X; and deuterated derivatives and pharmaceutically acceptable salts thereof.

[0434] 173. The use of any one of embodiments 169 to 172, wherein the one or more additional therapeutic agents comprises at least one compound selected from the group consisting of PTI-428, ABBV-2222, ABBV-2851, GLPG2737, ABBV-3221, ABBV-3748, ABBV-3903, ABBV-119, ABBV-2851, FDL-169, ARN5562, ARN21586, ARN22081, ARN22652, ARN23765, ARN23766, and PTI-801.

[0435] 174. The use of any one of embodiments 169 to 173, wherein the one or more additional therapeutic agents comprises a CFTR potentiator enhancer.

[0436] 175. The use according to any one of embodiments 169 to 174, wherein the one or more additional therapeutic agents comprises ASP-11.

[0437] 176. The use of any one of embodiments 169 to 175, wherein the one or more additional therapeutic agents comprises a CFTR potentiator.

[0438] 177. The use of any one of embodiments 169 to 176, wherein the one or more additional therapeutic agents comprises a compound selected from the group consisting of Compound III; Compound III-d; and deuterated derivatives and pharmaceutically acceptable salts thereof.

[0439] 178. The use of any one of embodiments 169 to 177, wherein the one or more additional therapeutic agents comprises at least one compound selected from the group consisting of FDL-176, PTI-808, GLPG1837 / ABBV-974, GLPG2451 / ABBV-2451, QBW251 (Isencattor), GLPG3067 / ABBV-3067 (Navocattor), and ABBV-191.

[0440] 179. The use of any one of embodiments 169 to 178, wherein the one or more additional therapeutic agents comprises a CFTR amplifier.

[0441] 180. The use of any one of embodiments 169 to 179, wherein the one or more additional therapeutic agents comprises PTI-428.

[0442] 181. The use of any one of embodiments 169 to 180, wherein the one ...

Claims

1. A method for treating cystic fibrosis, the method comprising administering to a patient in need thereof 0.1 mg to about 50 mg of Compound I per day: Or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

2. The method of claim 1, wherein the method comprises administering from about 0.25 mg to about 50 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

3. The method of claim 1 or claim 2, wherein the method comprises administering from about 0.25 mg to about 25 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

4. The method according to any one of claims 1 to 3, wherein the method comprises administering from about 1 mg to about 15 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

5. The method of any one of claims 1 to 4, wherein the method comprises administering from about 1.5 mg to about 14 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

6. The method of any one of claims 1 to 5, wherein the method comprises administering from about 4 mg to about 13 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

7. The method of any one of claims 1 to 6, wherein the method comprises administering from about 8 mg to about 13 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

8. The method of claim 1, wherein the method comprises administering from about 10 mg to about 40 mg of Compound 1 or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

9. The method of claim 1, wherein about 0.1 mg, about 0.25 mg, about 1 mg, about 1.5 mg, about 2.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, about 13 mg, about 14 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg or about 50 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

10. A method of treating cystic fibrosis, the method comprising administering to a patient in need thereof from about 0.1 mg to about 50 mg per day of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof, and wherein the patient is heterozygous and has one F508del mutation.

11. The method of claim 10, wherein the method comprises administering from about 0.25 mg to about 50 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day, and wherein the patient is heterozygous and has one F508del mutation.

12. The method of claim 10 or claim 11, wherein the method comprises administering from about 0.25 mg to about 25 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day, and wherein the patient is heterozygous and has one F508del mutation.

13. The method of any one of claims 10 to 12, wherein the method comprises administering from about 1 mg to about 15 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day, and wherein the patient is heterozygous and has one F508del mutation.

14. The method of any one of claims 10 to 13, wherein the method comprises administering from about 1.5 mg to about 14 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day, and wherein the patient is heterozygous and has one F508del mutation.

15. The method of any one of claims 10 to 14, wherein the method comprises administering from about 4 mg to about 13 mg per day of Compound I, or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof, and wherein the patient is heterozygous and has one F508del mutation.

16. The method of any one of claims 10 to 15, wherein the method comprises administering from about 8 mg to about 13 mg per day of Compound 1, or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof, and wherein the patient is heterozygous and has one F508del mutation.

17. The method of claim 10, wherein the method comprises administering from about 10 mg to about 40 mg of Compound 1 or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

18. The method of claim 10, wherein about 0.1 mg, about 0.25 mg, about 1 mg, about 1.5 mg, about 2.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, about 13 mg, about 13.5 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 21 mg, about 22 mg, about 23 mg, about 24 mg, about 25 mg, about 26 mg, about 27 mg, about 28 mg, about 29 mg, about 30 mg, about 31 mg, about 32 mg, about 33 mg, about 34 mg, about 35 mg, about 36 mg, about 37 mg, about 38 mg, about 39 mg, about 40 mg, about 41 mg, about 42 mg, about 43 mg, about 44 mg, about 45 mg, about 46 mg, about 47 mg, about 48 mg, about 49 mg, about 13 mg, about 14 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27.5 mg, about 30 mg, about 32.5 mg, about 35 mg, about 37.5 mg, about 40 mg, about 42.5 mg, about 45 mg, about 47.5 mg or about 50 mg of Compound 1 or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof, and wherein the patient is heterozygous and has one F508del mutation.

19. The method of any one of claims 1 to 18, wherein Compound I or a deuterated derivative or pharmaceutically acceptable salt thereof is administered in a single dose once daily.

20. The method of any one of claims 1 to 18, wherein Compound 1 or a deuterated derivative or pharmaceutically acceptable salt thereof is administered in two doses per day.

21. The method of any one of claims 1 to 20, further comprising administering one or more additional therapeutic agents.

22. The method of claim 21, wherein the one or more additional therapeutic agents comprises a compound having CFTR modulating activity or a deuterated derivative or a pharmaceutically acceptable salt thereof.

23. The method of claim 21 or claim 22, wherein the one or more additional therapeutic agents comprises a CFTR corrector.

24. The method of any one of claims 21 to 23, wherein the one or more additional therapeutic agents comprises a compound selected from: (a) (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylprop-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound II): (b) 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound IV): (c) N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound V): (d) N-(Benzenesulfonyl)-6-[3-[2-[1-(trifluoromethyl)cyclopropyl]ethoxy]pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound VI): (e) (14S)-8-[3-(2-{dispiro[2.0.2.1]hept-7-yl}ethoxy)-1H-pyrazol-1-yl]-12,12-dimethyl-2λ 6 -Thia-3,9,11,18,23-pentazatetracyclo[17.3.1.111,14.05,10]tetracosyl-1(22),5,7,9,19(23),20-hexaene-2,2,4-trione (Compound VII): (f) (11R)-6-(2,6-dimethylphenyl)-11-(2-methylpropyl)-12-{spiro[2.3]hexan-5-yl}-9-oxa-2λ 6 -Thia-3,5,12,19-tetraazatricyclo[12.3.1.14,8]nonadecaned 1(17),4(19),5,7,14(18),15-hexaene-2,2,13-trione (Compound VIII): (g) N-(Benzenesulfonyl)-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound IX): (h) N-[(6-amino-2-pyridinyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound X): and deuterated derivatives and pharmaceutically acceptable salts thereof.

25. The method of any one of claims 21 to 24, wherein the one or more additional therapeutic agents comprises a CFTR potentiator.

26. The method of any one of claims 21 to 25, wherein the one or more additional therapeutic agents comprises a compound selected from: (a) N-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (Compound III): (b) N-(2-(tert-butyl)-5-hydroxy-4-(2-(methyl-d3)propan-2-yl-1,1,1,3,3,3-d6)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (Compound III-d): and deuterated derivatives and pharmaceutically acceptable salts thereof.

27. A pharmaceutical composition comprising about 0.1 mg to about 50 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

28. The pharmaceutical composition of claim 27, wherein the composition comprises about 0.25 mg to about 50 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

29. A pharmaceutical composition according to claim 27 or claim 28, wherein the composition comprises about 0.25 mg to about 25 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

30. The pharmaceutical composition of any one of claims 27 to 29, wherein the composition comprises about 1 mg to about 15 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

31. The pharmaceutical composition of any one of claims 27 to 30, wherein the composition comprises about 1.5 mg to about 14 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

32. The pharmaceutical composition of any one of claims 27 to 31, wherein the composition comprises about 4 mg to about 13 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

33. The pharmaceutical composition of any one of claims 27 to 32, wherein the composition comprises about 8 mg to about 13 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

34. The pharmaceutical composition of claim 27, wherein the composition comprises about 10 mg to about 40 mg of Compound 1 or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

35. The pharmaceutical composition of claim 27, wherein the composition comprises about 0.1 mg, about 0.25 mg, about 1 mg, about 1.5 mg, about 2.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 About 150 mg, about 160 mg, about 180 mg, about 250 mg, about 260 mg, about 280 mg, about 290 mg, about 300 mg, about 320 mg, about 350 mg, about 370 mg, about 370 mg, about 400 mg, about 420 mg, about 450 mg, about 470 mg, or about 500 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.

36. A pharmaceutical composition according to any one of claims 27 to 35, wherein the composition further comprises one or more additional therapeutic agents.

37. The pharmaceutical composition of claim 36, wherein the one or more additional therapeutic agents comprises a compound having CFTR modulating activity or a deuterated derivative or a pharmaceutically acceptable salt thereof.

38. The pharmaceutical composition of claim 36 or claim 37, wherein the one or more additional therapeutic agents comprises a CFTR corrector.

39. A pharmaceutical composition according to any one of claims 36 to 38, wherein the one or more additional therapeutic agents comprises a compound selected from: (h) Compound II; (i) Compound IV; (j) Compound V; (k) Compound VI; (1) Compound VII; (m) Compound VIII; (n) Compound IX; as well as (i) Compound X; and deuterated derivatives and pharmaceutically acceptable salts thereof.

40. The pharmaceutical composition of any one of claims 36 to 39, wherein the one or more additional therapeutic agents comprises a CFTR potentiator.

41. The pharmaceutical composition of any one of claims 36 to 40, wherein the one or more additional therapeutic agents comprises a compound selected from the group consisting of Compound III; Compound III-d; and deuterated derivatives and pharmaceutically acceptable salts thereof.

42. Compound I or a deuterated derivative or a pharmaceutically acceptable salt or a pharmaceutical composition according to any one of claims 27 to 41, for use in a method of treating cystic fibrosis in a patient, the method comprising administering about 0.1 mg to about 50 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof per day.

43. Use of Compound I or a deuterated derivative or a pharmaceutically acceptable salt thereof or a pharmaceutical composition according to any one of claims 27 to 41 for the preparation of a medicament for the treatment of cystic fibrosis, wherein the medicament comprises about 0.1 mg to about 50 mg of Compound I or an equivalent amount of a deuterated derivative or a pharmaceutically acceptable salt thereof.